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Since the approval of the first therapeutic monoclonal antibody in 1986, monoclonal antibody has 
become an important class of drugs within the biopharmaceutical industry, with indications and 
superior efficacy across multiple therapeutic areas, such as oncology and immunology. Although 
there has been great advance in this field, there are still challenges that hinder or delay the 
development and approval of new antibodies.  
 
For example, we have seen issues in manufacturing, such as quality, process inconsistency and 
large manufacturing cost, which can be attributed to production failure, delay in approval and drug 
shortage. Recently, the development of new technologies, such as Process Analytical Tools (PCT), 
and the use of statistical tools, such as quality by design (QbD), Design of Experiment (DoE) and 
Statistical Process Control (SPC), has enabled us to identify critical process parameters and 
attributes, and monitor manufacturing performance.  
 
However, these methods might not be reliable or comprehensive enough to accurately describe the 
relationship between critical process parameters and attributes, or still lack the ability to forecast 
manufacturing performance. In this work, by utilizing multiple modeling approaches, we have 
 
 
developed a systematic framework to optimize and control monoclonal antibody manufacturing 
process.   
 
In our first study, we leverage DoE-PCA approach to unambiguously identify critical process 
parameters to improve process yield and cost of goods, followed by the use of Monte Carlo 
simulation to validate the impact of parameters on these attributes. In our second study, we use a 
Bayesian approach to predict product quality for future manufacturing batches, and hence 
mitigation strategies can be put in place if the data suggest a potential deviation. Finally, we use 
neural network model to accurately characterize the impurity reduction of each purification step, 
and ultimately use this model to develop acceptance criteria for the feed based on the 
predetermined process specifications.  Overall, the work in this thesis demonstrates that the 
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Monoclonal antibodies (mAb) have become an increasingly important class of therapeutic 
agents that contribute to several major advances in pharmacotherapy. Over the past decade, 
FDA has approved more than 15 new therapeutic antibody products spanning four major 
therapeutic areas [1], with 52% in immunology, 36% in oncology, 4% in infectious diseases, 
and 8% in other areas [2]. For antibody products that are currently in development, more than 
half (59%) are in the area of oncology [2]. In the past few years, FDA granted breakthrough 
designation and accelerated approval of several oncology mAbs such as Keytruda® (Merck) 
and Opdivo® (Bristol – Myers Squibb). These mAb drugs have shown breakthrough results in 
the treatment of melanoma and small cell lung cancer. In fact, the continued interest in antibody 
product development is partially driven by the rapid advancement of our understanding of 
diseases at a molecular level. Compared to small molecule products, mAbs often show higher 
efficacy and better safety, because they provide the most rapid route to a clinical proof-of-
concept for activating, inhibiting or blocking disease targets, with minimal off target effects 
[3]. The market for monoclonal antibodies is rapidly expanding – the global sales revenue for 
all monoclonal antibody products was nearly $75 billion in 2013, and it represents the industry 
segment with the highest growth rate over the last decade [4, 5]. 
 
To respond to the increasing market demand and competition for mAbs, biopharmaceutical 
companies, in collaboration with academia, are looking to streamline the drug development 
process, implement stringent control of product quality and optimize manufacturing processes 
to reduce production cost. However, the development and manufacture of biopharmaceutical 
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drugs is a highly complex endeavor that is heavily regulated [6, 7]. This has stimulated 
discussions within the industry on the best route for monoclonal antibody development.  
 
The recent advancement in expression technology has significantly increased the cell culture 
titer, and hence improved the productivity of the mAb upstream production. However, this has 
shifted the bottleneck to the downstream production, where the increase in downstream 
production cost can potentially negate the gain in titer and overall process throughput. Hence, 
biopharmaceutical companies explore different strategies to reduce the cost for mAb 
downstream processing. This gives rise to a significant opportunity for a decisional framework 
capable of comparing multiple optimization strategies and guiding decision makers towards 
the selection of an effective strategy.  
 
In addition to reduce manufacturing cost through process optimization, biopharmaceutical 
companies focus on ensuring process and quality consistency, and ultimately minimizing 
process deviation and batch failures. To achieve this, it is imperative for these companies to 
develop methodologies to monitor and predict manufacturing performance. Hence, should a 
potential deviation be suspected, mitigation strategies can be developed in advance to minimize 
the risk. Furthermore, to ensure product consistency, and drug product meeting the final 
specification for safety and efficacy, it requires a development of appropriate specification for 
process intermediates in a complex multistep process. Although advanced qualitative methods, 
mathematical and statistical models have been used in various aspects of pharmaceutical drug 
development and manufacturing, such as clinical [8], and product quality risk quantification 
[9], application of such tools in predicting manufacturing performance, or setting process 
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intermediates specification, are yet to be developed. Consequently, the aim of this thesis is the 
development of a decisional framework for manufacturing process optimization, and 
quantitative tools to ensure manufacturing consistency and product quality.  
 
The introductory chapter provides an overview of the biopharmaceutical industry, the 
increased demand for monoclonal antibody drugs, and the intense pressure within the industry, 
as more products, including novel and generic products, are coming to the market. Section 1.1 
provides an overview of the drug development process in the biopharmaceutical industry, from 
basic discovery, preclinical, clinical and large scale commercialization. Section 1.2 focuses on 
monoclonal antibody as therapeutic drugs and reviews the current approved mAb drugs, their 
structure and the production process to manufacture mAb drugs. Section 1.3 discusses the 
various issues and complexities in mAb manufacturing, and how the regulatory agencies 
mandate the use of process characterization, process validation and monitoring to ensure 
process robustness and product quality. There is an overview of the different tools and 
approaches that biopharmaceutical companies utilize for process characterization, validation 
and monitoring, to reduce product failures. In addition to ensuring product consistency and 
quality, this section discusses how biopharmaceutical companies try to reduce manufacturing 
cost through process optimization, and thus make their products more cost effective. Finally, 
in Section 1.4 the aims and organization of the thesis are presented.  
 




Developing a new drug from original idea to the launch of a finished product is a complex 
process which can take 12-15 years and cost in excess of $1 billion [10]. This process consists 
of four major steps: discovery and development, preclinical research, clinical research, and 
final approval (Fig 1.1). Discovery and development can be further broken down into four 
steps: target identification, target validation, lead identification and lead optimization. Target 
identification and validation is the process of identifying a potential target for a therapeutic 
drug for a particular disease or condition that does not have a treatment or for which existing 
therapeutic agents are lacking in some way [11]. After the target has been identified and 
validated, multiple drug candidates are then developed and further optimized. Drug candidate 
leads must be shown to reach the target and modulate its activity in vivo while acting within 
acceptable safety margins [11].  
 
Fig 1.1 Overview of drug development process 
Before testing a drug in human, research must be conducted in animals to determine whether 
it has the potential to cause serious harm, or toxicity. During this preclinical stage, studies in 
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animal models are combined with cellular and biochemical assays to understand the 
pharmacological and toxicity profile in at least two animal species. Early dosage studies are 
also performed to guide dose selection in the upcoming first in human studies [11].  
 
Clinical trials consist of three major phases: Phase I, II and II. In phase I studies, the leading 
drug candidate is usually tested in healthy volunteer, at different dosages, to assess the safety 
of the drug. Phase I clinical trials often last several months to a year, and about 60% of 
experimental drugs pass this phase of testing (Fig 1.2). Upon the successful completion of 
phase I studies, the drug candidate is then tested in the target patient population to evaluate the 
safety and efficacy. Most phase II studies are randomized trials where one group of patients 
receive the experimental drug, while a second “control” group receives a standard treatment or 
placebo. This allows the investigators to assess the relative safety and effectiveness of the new 
drug against placebo or standard therapy.  
 
Phase II studies can last from several months to two years, and about one-third of experimental 
drugs success complete this phase of testing. Phase III studies often involve randomized and 
blind testing in several hundred to several thousand patients. This is the largest scale of testing 
of all phases and it can last for several years. Results from Phase III studies should provide the 
pharmaceutical company and the FDA with a more thorough understanding of the 
effectiveness of the drug, the benefits and the range of possible adverse effects. Of the 
experimental drugs that enter the phase III studies, about 60% of them successfully pass this 
stage (Fig 1.2). Once phase III is complete, a pharmaceutical company can request FDA 





Fig. 1.2 Phase transition success rates for all diseases, all modalities [12,13] 
 
 
The required production quantities of the experimental drug increase as the developmental 
stage progresses from discovery through development to large-scale manufacturing. Design 
and optimization of production scale-up, also known as process development, requires careful 
testing and monitoring using a wide range of different techniques including protein 
purification, analysis, quantification and identification tools at every step.   
 
After final FDA approval of a new drug, large-scale manufacturing can begin. Pharmaceutical 
manufacturing requires continual monitoring of all aspects of the process: raw ingredients, 
manufacture, packaging, and storage, to ensure process consistency and product quality.  
 




Since the approval and commercialization of the first therapeutic monoclonal antibody in 1986, 
Orthoclone OKT3, which was used for prevention of kidney transplant rejection, therapeutic 
monoclonal antibodies and antibody-related products such as Fc-fusion protein, antibody 
fragments and antibody-drug conjugates have become the dominant class within the 
biopharmaceutical industry [14]. Monoclonal antibody products today are approved for a 
variety of indications, such as cancer, inflammatory/autoimmune diseases, transplant rejection 
and infectious diseases.  
 
Some of the well-known monoclonal antibody drugs include Avastin, Humira, Herceptin, 
Enbrel, Remicade, Rituxan, Yervoy, Keytruda and Opdivo. Annual approvals of monoclonal 
antibody products have increases significantly since 1982. Based on an approval rate of 
approximately four monoclonal antibody products per year, it is anticipated that there will be 
70 or more monoclonal antibody products on the market by 2020 [14].  
 
In addition to an increased approval rate, global sales of monoclonal antibody products have 
grown from ~$38 billion in 2008 to almost $63 billion in 2013 [14]. Compared to other class 
of therapeutic drugs, monoclonal antibody has become the dominant segment with the 
strongest growth (Table 1.1) [16]. Sales per gram of mAb range from $1000 per gram to $50, 
000 per gram depending on dosage [17, 18]. Biopharmaceuticals are so expensive partly due 
to the high cost of manufacturing and the relatively lower bioavailability, and consequently 





Sales ($ billion) 
Molecule Type 2009 2010 2011 2012 2013 2014 Difference in 
sales between 
2009 and 2014 
Small Molecule 411 414 415 405 394 394 -4% 
Therapeutic Protein 65 68 70 72 74 76 17% 
Monoclonal Antibody 38 43 48 53 58 62 63% 
Vaccine 21 22 24 25 27 28 33% 




1.2.1 Monoclonal Antibody structure  
 
Each monoclonal antibody is composed of two identical heavy polypeptide chains (Fig 1.3). 
These chains are each held together by disulfide bonds. Both the heavy and light chains are 
made up of folded regions, called domains. Light chains (LC) contain one variable region 
(denoted V for variable) and one constant region (denoted C for constant). Similarly, heavy 
chains (HC) contain one variable and three or four constant regions depending on the antibody 





Fig. 1.3 Basic structure of a monoclonal antibody [15] 
 
The amino acid sequences in the variable regions are varied among antibodies from different 
B-cell lineages. However, the constant regions are relatively conserved across different classes 
of antibodies. In addition to the basic structure, antibodies are naturally glycosylated along the 
heavy chain [15]. The pattern of glycosylation often have a strong impact on the actions of the 
antibody, including proper secretion, kinetic in circulation, and the chemistry related to proper 




1.2.2. Manufacture of Monoclonal Antibodies 
Mammalian cells are typically used for expression of all commercial therapeutic mAbs, and 
grown in suspension culture in large bioreactors [17]. Majority of commercial mAbs are 
derived from Chinese Hamster Ovary, or CHO cells. Several characteristics have made CHO 
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cell the most dominant cell line in antibody production, such as rapid growth, high expression, 
and the ability to be adapted for growth in chemically-defined media [17]. Table 1.2 shows a 
selected list of commercial mAbs produced in CHO cells [18]. A typical bioreactor production 
process lasts for 7 – 14 days with periodic feeds added to the bioreactor. These fed-batch 
processes will accumulate mAb titers of 1-5 g/L, with some companies reporting 10-15 g/L for 
extended culture durations. Production bioreactor volumes can range from 5 kL to 25 kL.  
 
Product Indication Marketing company First US approval 
Rituximab(RituxanTM) Chronic lymphocytic leukemia Genentech, Biogen Idec 1997 
Trastuzumab(HerceptinTM) Breast cancer Genentech 1998 
Alemtuzumab(CampathTM) Chronic lymphocytic leukemia Genzyme 2001 
Omalizumab(XolairTM) Allergic asthma Genentech 2003 
Bevacizumab(AvastinTM) Colorectal cancer Genentech 2004 
Panitumumab(VectibixTM) Colorectal cancer Amgen 2006 
Tocilizumab(ActemraTM) Rheumatoid arthritis Chugai/Roche 2010 
Table 1.2 Selected list of approved antibodies produced in CHO cells [18] 
 
A typical cell culture process, or upstream process (USP), consists of a number of unit 
operations, including cell bank vial thaw, seed train, inoculum train, production culture and 
primary recovery, or harvest (Fig  1.4). After the cell bank vial is thawed, the cells will grow 
in the seed train. When the cells reach a specific density, they are then inoculated. During the 
inoculum train, the cell will continue to grow and expand. The cells are then transferred to the 
production bioreactor, which ranges from 5 kL to 25 kL, for commercial production. 





Upon the completion of the production bioreactor, the harvested cell culture bulk is processed 
by centrifugation, followed by depth filtration to remove the mammalian cells. This step is 
known as primary recovery, and the resulting harvested cell culture fluid (HCCF) is then 
clarified by a series of downstream purification steps.  
 
Figure 1.5 shows an example of a monoclonal antibody downstream purification process 
(DSP). The HCCF is initially clarified by the Protein A chromatography step. This step 
typically operates in bind-and-elute mode, in which the monoclonal antibody initially binds to 
the Protein A resin, while the impurities, such as host cell protein (HCP), DNA and aggregates 
pass through.  The low-pH product elution step at the end of the Protein A also acts as a virus 
inactivation step by denaturing enveloped viruses.  
 
 




Subsequently, the Protein A eluate is further polished by two additional ion exchange steps. 
The ion exchange steps can operate either in bind-and-elute or flow-through mode, where the 
product of interest either bind to the resin initially, and the impurity will flow through, or vice 
versa. The most common forms of ion exchange chromatography are anion exchange (AEX) 
and cation exchange (CEX). While both of these polishing steps are utilized to remove 
impurities, such as HCP, DNA, leached Protein A ligand and aggregate, the AEX step can 
further reduce adventitious viruses.  
 
After the two ion exchange steps, the product stream is then processed through a virus filtration 
step (VF), another step dedicated for virus reduction. This step utilizes nanofiltration to remove 
viruses by size exclusion. Finally, an ultrafiltration/diafiltration step is carried out to 
concentrate the product stream to a specified concentration and formulate it, in order to achieve 
efficacy and bioavailability.  
 
Fig 1.5 Overview of a typical monoclonal antibody downstream process (DSP)  
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1.3 Manufacturing Issues 
 
1.3.1 Biopharmaceutical Manufacturing Principles 
 
The real goal of biopharmaceutical manufacturing is to provide product that reflects the 
material used in clinical trials regarding safety and efficacy, in a consistent way [20]. There 
might be changes throughout clinical manufacturing and commercial production, due to 
various reasons, such as changes in scale, manufacturing site and raw material source. 
However, these changes should only have minimal impact on product quality and overall 
output.  
 
To achieve a robust manufacturing process, it is imperative to ensure that the process is well 
characterized, in other words, the relationships between critical process parameters (CPP) and 
critical quality attributes (CQA) are well understood. Furthermore, to ensure consistency from 
batch to batch, process control tools are often utilized to track the performance of each 
manufacturing batch, and to identify any potential trend.  
 
 
1.3.2. Overview of product failure 
 
Pharmaceutical product failure can often be attributed to three critical areas: medical utility 
(efficacy), safety and industrialization (manufacturing and quality) [21]. One frequent reason 
for product failure is that the product doesn’t show efficacy in clinical trials [20]. Ideally, we 
would want to pick up this issue early on in the development phase, such as Phase II studies. 
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However, in many cases, it has taken a large and costly pivotal study to reveal lack of efficacy 
[20]. Hence it is important to choose the right indication, appropriate clinical end points and 
select a good study design to support the benefits of a drug candidate [22]. In addition to 
efficacy, any safety concerns during the clinical trials, or even post registration, can delay the 
product to the market, stop the further development and even recall the product from the 
market.  
 
Although manufacturing issues are usually not the major cause of product failure [23], 
manufacturing problems can significantly delay product approval for complex biotechnology 
drugs [20]. The lack of manufacturing consistency or the initiation of manufacturing changes 
late in product development [24] has delayed approval of monoclonal antibody products [20]. 
Some of the typical manufacturing issues include failure to comply with the final drug 
substance or drug product specification, lack of process and product consistency, 
contamination, and other types of deviations.  
 
In the past, manufacturing cost has rarely been the cause of product failure. However, as the 
competition in the biopharmaceutical industry becomes more and more intense recently, and 
the drug market becomes more crowded, having a high manufacturing cost might make the 
products, especially if it’s not first to market, less competitive, or in the worst case, not be able 
to generate sufficient profit to justify the development. Hence, while companies are putting in 
a lot of efforts to ensure efficacy, safety and manufacturing robustness, more and more 
companies are starting to also focus their development to optimize their manufacturing 
processes to improve cost of goods.  
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1.3.3. Product Specification, Process Characterization and Validation, Process Monitoring 
 
To ensure a robust and consistent manufacturing process, the triad of process control (e.g. raw 
material acceptance criteria, in-process testing, defined setpoints and operating range for 
process parameters and defined process and hold times), process validation and product testing 
are the basis for current manufacturing of monoclonal antibodies and the majority of 
pharmaceuticals [20].  
 
 
1.3.3.1. Product Specification 
 
The safety and efficacy of biopharmaceutical products are paramount to their successful 
commercialization. Product specifications have long been regarded a safeguard with respect to 
product efficacy and safety [25]. A specification is defined as a list of tests, references to 
analytical procedures and appropriate acceptance criteria to which drug product or materials at 
other stages of its manufacture should conform to be considered acceptable for its intended use 
[26]. Specifications lead to a tradeoff between the likelihood a consumer will acquire a 
suboptimal dose and the likelihood a lot will fail release [20]. Hence, it is important to focus 
on relevant attributes and set acceptance criteria that are relevant to risks. Consumers can then 




Table 1.3 Typical release tests used for monoclonal antibody products [25]. 
 
Table 1.3 shows a list of typical release tests that have been reported in various literatures for 
monoclonal antibody manufacturing [25, 27]. These tests include various indicators, such as 
quantity (measured by protein concentration), purity (measured by various modes of 
chromatography), identity (measured by electrophoresis and peptide mapping), potency 
(measured by antigen binding assay), impurities (measured by DNA, HCP and endotoxin 
assays), and general properties (pH, volume and color). For each of these critical attributes, a 
specification is set for the final product, as well as some of the intermediate products.  
 
Each specification has three key elements [25, 28, 29]: 
• A Critical quality attribute or process parameter that the specification is 
targeting 
• An analytical method that is used to perform the test 
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• Qualitative or quantitative acceptance criteria that determine acceptance or 
rejection of a manufacturing lot 
The first step to identify critical process parameters or quality attributes is to perform a risk 
assessment, and understand the relationship of each parameter and attribute with respect to 
clinical efficacy and safety. For each unit operation in both upstream and downstream 
processes, each of the process parameters, as well as, quality attributes, is assessed in terms of 
its impact on safety and efficacy, in case the process falls out of the pre-specified range. The 
risk score can be both quantitative and qualitative.  
 
Table 1.4 shows an example of risk assessment of quality attributes in various process steps. 
The scores are given based on previous process knowledge, literature and process 
characterization studies, which will be discussed in subsequent sections. The quality attributes 
or process parameters that have a high risk, or sometime medium risk, are categorized as 






Table 1.4 Example of risk assessment for quality attributes in each unit operation [30] 
 
 
After identifying CQAs, specifications need to be set for these CQAs to ensure the final drug 
substance or drug product confers safety and efficacy. Figure 1.6 illustrates an approach for 
setting specifications for product quality attributes. Setting product specifications requires 
sifting through a variety of data from various sources, such as clinical studies, animal models, 
pharmacokinetic studies, characterization of process capability, analytical method capability, 










While it is very common to use process capability, or ability of a particular step to remove 
impurities, to set specification for critical quality attributes, it is important to assess process 
capability accurately. One approach is to develop a mechanistic model of a specific process, 
and leverage this model to predict the input specification based on the final output 
specification. However, this approach is very process specific, and would involve significant 
amount of time and effort for model development. Hence, this approach is rarely used for 
acceptance criteria setting.  
 
Another way to understand process capability is to do a worst case scenario study. In such 
study, we challenge the chromatography column or filter with a significant higher than typical 
amount of impurity, and find out the maximum impurity reduction this step can achieve. A 
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challenge with this approach is that sometimes it could be difficult to find a feed stream with 
such a high impurity level while ensuring these impurities are representative. In addition, a lot 
of experiments need to be conducted before we are able to reach the saturation point.  
 
Some other simpler approach used in the industry to understand process capability is to 
compare the average impurity levels of the feed and the product, and the average reduction is 
used to calculate the in-process acceptance criteria. While this is relatively straightforward, 
one caveat is that it assumes that the impurity clearance is independent of the feed impurity 
level. For instance, two feeds with different impurity levels are assumed to undergo the same 
degree of reduction; however, this is not always the case, as shown later in our study. This 
analysis also represents a need for a better tool to characterization process capability in 






1.3.3.2. Process Characterization 
 
As discussed earlier, process characterization is one approach that the industry uses widely to 
establish critical process parameters that have significant impact on product quality. Figure 1.7 
shows an overview of the different steps in process characterization. An initial risk assessment 
is performed on all process parameters in each unit operation. Based on development history 
21 
 
and previous process knowledge, each process parameter is assigned a risk score. Based on the 
internal  score cutoff for high risk parameters, those that have a high risk score are categorized 




Figure 1.7 Overview of Process Characterization 
 
 
During the second phase of process characterization, experimental studies, designed using 
various statistical tools, such as OFAT (one factor at a time), DoE (design of experiment), PCA 
(principal component analysis), are carried out to understand the relationship between each 
potential process parameter and critical quality attributes. These analyses, combined with 
process knowledge and experience, determine which parameters are both statistically and 
practically significant. For those that have both significance, we categorize them as critical 
Parameter Designation
Label parameters that have significant impacts as CPP
Experimental Study
Study impact of each potential parameter on 
critical quality attributes
Evaluate whether the impact is statistically and 
practically significant 
Initial Risk Assessment
Evaluate each process parameter in all unit 
operations
Identify potential critical process parameters
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process parameters, or CPPs. During manufacturing, it is crucial to implement stringent control 
on these parameters to ensure that all process intermediates or drug substance meet the 
specification to achieve efficacy and safety.  
 
 
1.3.3.3. Process Validation 
 
The definition of ‘process validation,’ also known as process qualification, is to gather 
statistically sufficient evidence that the process is empirically understood and under control 
[31]. Process validation is required to perform prior to obtaining product approval.  
 
The most recent ICH and FDA guidance endorse a new paradigm of process validation, based 
more on process understanding and control of critical parameters and less on product testing 
[30]. Table 1.5 lists the steps to test the robustness of a process. Steps 1-3 are part of the process 
characterization. After identifying the CPPs and quantifying their impact on product quality, 
process validation, which is step 4, is conducted to demonstrate the critical parameters can be 
monitored and controlled at commercial scale batches. Typically, FDA requires manufacturers 
to demonstrate that their process is able to perform consistently, without any major deviation, 
in at least three consecutive batches. At the end of each batch, the drug substance and drug 
products need to meet all the specification in order to successfully pass process validation.  
 
 
1 Identification of critical variables relating to the 
reproducibility of the process 
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2 Determination of the ranges for these variables 
based on a sound empirical understanding of the 
process 
3 Quantification of variable effects and 
interactions at the extremes of their ranges 
4 Demonstration that critical variables can be 
monitored and controlled during manufacturing 
runs 






In addition to demonstrate process consistency and robustness in three consecutive batches, 
the new FDA guidance points to a lifecycle approach to process validation. As shown in Figure 
1.8, the lifecycle approach consists of three stages: process design, process qualification and 
process monitoring [30]. While the first two stages have been part of the traditional approach, 
continuous process monitoring (1.3.3.4) is a new added stage in the lifecycle approach.  
 
 
Figure 1.8 Lifecycle approach to process validation [30] 
 




As discussed in 1.3.3.3, continuous process monitoring, which monitors critical process 
parameters as part of annual product review and other monitoring programs, has now been part 
of the new process validation process. Further, continuous monitoring is beneficial to the 
manufacturers, because if the process trends suggest some potential deviation, mitigation 
strategies can be developed in advance to minimize the risks.  
 
Statistical tools, such as Shewart control chart, are used to monitor critical process parameters 
and critical quality attributes, and to ultimately ensure that they are within the predetermined 
process control limits, or specification. In addition to monitoring past batches performance, the 
ability to leverage historical knowledge to predict the performance of future batches is very 
critical.  
 
Although advanced quantitative methods, mathematical and statistical models have been in 
used in various aspects of pharmaceutical drug development and manufacturing, such as clinical 
[32] and product quality risk quantification [33], application of such tools in predicting drug 
manufacturing performance is yet to be developed. The conventional approach, or the approach 
that is widely used in the industry, for predicting batch performance usually assumes the mean 
of the upcoming batch is equal to the mean of the historical batches. While this approach can 
give a reliable estimation when the all batches perform very consistently, it might not be 
sensitive to subtle changes in certain batches, especially when the sample size of the historical 
data is much larger than that of the recent data.  Hence, it is important to develop a more reliable 
and accurate tool to predict future performance of manufacturing batches, by leveraging 
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historical information. This way, we can minimize process deviation, product failure and 




1.3.4. Process Optimization to reduce cost of goods 
 
To meet the increasing demand for monoclonal antibody products, and the increasing 
competition within the industry, biopharmaceutical companies been constantly looking for 
ways to improve manufacturing productivity while trying to reduce the overall cost, or cost of 
goods (COGS). As discussed earlier, bioprocesses have to be carefully fine-tuned to ensure the 
consistent quality of the material produced, and initiatives such as Quality by Design (QbD) 
should result in the development of robust and flexible processes [4].  
 
In addition, pressure from competition, such as molecules being approved for the same 
indications, patent expiry, and the arrival of generics, will put increased pressure on sale prices. 
Hence, minimizing the production cost will give a manufacturer a competitive edge in 
maintaining economically viable products [4,34,35,36,37].  
 
Monoclonal antibody production cost can be often broken down to five categories: raw 
materials, consumables, labor, facility and other (Table 1.6). While facility and other costs are 
fixed once the manufacturing facility is set, costs, such as raw materials, consumables and 




Raw materials Water, components used in process, cleaning 
media, and buffers 
Consumables Chromatography resins, filters, disposable bags 
Labor Dedicated labor process cost 
Quality assurance and quality control 
Other 
Facility Fixed equipment cost 
Building, maintenance, installation, and 
pipework expressed as a factor of the total 
equipment purchase 
Other Insurance, spares, utilities, contractor’s fee, and 
contingency expressed as a factor of the total 
equipment purchase 





With the recent advancement in process simulation software, there are a number of software 
tools that the industry often uses to analyze cost for pharmaceutical manufacturing. 
Specifically, for monoclonal antibody production, SuperPro Designer has been one of the most 
dominant process simulation tools used by the industry [4]. SuperPro Designer takes into 
account all the process steps (figure 1.9), including process parameters (flow rate, number of 
chromatography cycles, size of equipment, volume of buffer charged), types of consumable 
used, and all the associated costs.  
 
Additionally, fixed costs related to the infrastructure, such as building and equipment, can also 
be incorporated in the calculation. The output of the process model includes overall throughput 
and cost, throughput and cost for each step, and the cost breakdown in terms of the five 
categories shown above. These results are useful in pinpointing steps, which have the high 





Figure 1.9 Example of SuperPro Design Model of Monoclonal Antibody Production Process [4]. 
 
 
Owing to the improvement in the cell culture process, and the advance in expression 
technology, the cell culture titer coming out of the bioreactor has increased from below 1g/L 
to 1-5 g/L, with some companies reporting 10-13 g/L for extended culture duration [17]. The 
increase in cell culture titer has shifted the manufacturing and economic bottleneck from 
upstream processing (USP) to downstream processing (DSP).  
 
Sommerfeld and Strube have shown that as cell culture titer increases from 0.1 to 1g/L, the 
ratio of USP to DSP costs drops from 55:45 to 30:70 [38]. At higher product titer, larger 
chromatography columns, membrane areas, buffer consumption and/or additional 
chromatography or filtration cycles would be required to purify the cell culture harvest from 
upstream. Experience in the industry shows [39] that the overall cost per gram of drug 
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substance purified initially decreases as titer increases. However, the cost plateaus as the titer 
increases further.  In a higher titer process, the increase in downstream cost can potentially 
negate the gains in titer, or overall process throughput. Hence, reducing downstream 
production cost through process optimization is an effective strategy to alleviate process 
bottleneck, and make the production process more cost effective.  
 
A Design of Experiment (DoE) approach has been used widely in the industry for process 
optimization [4]. DoE is very efficient in understanding the effect of parameters, their 
interactions, and generating a predictive model with a minimum number of experiments. As 
discussed previously, results from DoE can help us identify a list of statistically significant 
parameters; in this specific case, parameters that have significant impact on cost of goods. As 
a result, process development teams can develop strategies to further optimize these parameters 
to reduce downstream cost of goods.  
 
However, sometimes multiple statistically significant parameters are identified through the 
DoE study, but the resources available and timeline can only allow us to optimize a selected 
number of parameters. In this case, DoE might not be able to identify the relative importance 
of each parameter [39], or which parameters are more effective in reducing cost of goods. 
Hence, a new optimization approach, and an additional optimization tool, needs to develop to 







1.4  Aims & Organization of Thesis 
 
The preceding sections of this chapter have provided an introduction to biopharmaceutical drug 
development process, and highlighted the impact of monoclonal antibodies as an important 
class of therapeutic agents. With the intense competition within the industry, and the stringent 
product approval guidelines from the FDA, biopharmaceutical companies not only have to 
ensure their products show superior efficacy, safety, but also need to develop a manufacturing 
process that is robust, consistent and cost effective. In this section, we discussed the various 
ways that the biopharmaceutical industry practices to ensure product quality and consistency, 
and reduce costs. However, the presented literature review and industry survey highlighted that 
at present there is still a need to develop better tools to characterize process capability, predict 
biopharmaceutical manufacturing performance and optimize manufacturing processes to 
reduce cost of goods. 
 
Consequently, the aim of this thesis is the development of a systematic framework to optimize 
and control monoclonal antibody manufacturing process. This will facilitate more informed 
decision-making when identifying and evaluating process optimization strategies, leveraging 
historical manufacturing and development data to predict future manufacturing performance, 
and understanding process capability to enable in-process specification setting given the final 
product specification. In order to realize this aim, a set of objectives was established and these 




In Chapter 2, we present a framework to prioritize optimization strategies during monoclonal 
antibody process development. Design of Experiment (DoE), in conjunction with Principal 
Component Analysis (PCA), is employed to identify process parameters that have the most 
impact on downstream production cost. Statistically significant parameters are identified 
through a DoE study, while the PCA characterization is applied as an independent tool to 
further elucidate the relative importance of these parameters. A stochastic approach 
incorporating process uncertainties is used to illustrate the distribution of downstream cost of 
goods under different process conditions. Overall, this systematic approach is able to prioritize 
development strategies under compressed timeline, and enable biopharmaceutical companies 
to achieve a competitive advantage in today’s market.  
 
Chapter 3 presents a process prediction tool that is capable of leveraging available 
manufacturing and development data to predict the performance of future monoclonal antibody 
production batches. Hence, if a potential process deviation is suspected in an upcoming 
manufacturing batch, strategies can be developed in advance for risk mitigation. This chapter 
tries to estimate future process performance using both a conventional approach, or an 
approach that is widely used in the industry, and a Bayesian approach, which is proposed in 
our research. While both approaches arrive at a similar prediction when a process performs 
consistently, the Bayesian approach is better at capturing heterogeneity when there is 
inconsistency emerging in recent batches. Hence, in such case, the Bayesian approach enables 




Chapter 4 highlights the importance of setting appropriate acceptance criteria, or process 
specification, for process intermediates to increase the likelihood of the final drug substance 
and drug product meeting the final product release specification. When setting acceptance 
criteria for process intermediates, it is important to first understand process capability, or 
quantify the impurity clearance of each process step. However, this process involves either 
challenging experimentation or an estimation method that might not be comprehensive. 
Chapter 4 proposes the use of neural network to understand process capability. This approach 
not only is able to delineate the relationship between the feed and product impurity level for a 
specific step, but is also able to define the acceptance criteria for the feed impurity level based 
on a predetermined product impurity level. These acceptance criteria enable us to determine 
whether or not to forward process the step based on the feed impurity level.  
 
In Chapter 5 a summary of the main conclusions of this thesis is presented and some future 
directions of research to augment this work are presented. Finally, papers by the author, 









2 Integrating Design of Experiment and Principal Component 
Analysis to Reduce Downstream Cost of Goods in Monoclonal 




Monoclonal antibodies (mAb) have become an increasingly important class of agents that 
contribute to several major advances in pharmacotherapy. In the past few years, FDA has approved 
over 15 new therapeutic antibody products, and granted breakthrough designation and accelerated 
the approval of several oncology mAbs such as Keytruda (Merck) and Opdivo (Bristol-Myers 
Squibbs). Indeed, the market for monoclonal antibodies is rapidly expanding, and it represents the 
industry segment with the highest growth rate over the last decade [4]. 
 
To respond to the increasing market demand for mAbs, biotech and pharmaceutical industry, in 
collaboration with academia, have enhanced their strategies to increase bioprocessing productivity. 
Owing to the improvement in the cell culture process, and the advance in expression technology, 
mAbs product titer has increased from below 1 g/L to 1-5 g/L, with some companies reporting 10-
13 g/L for extended culture duration [17]. The increase in cell culture titer has shifted the 
manufacturing and economic bottleneck from upstream processing (USP) to downstream 
processing (DSP).  
 
Sommerfeld and Strube have shown that as cell culture titer increases from 0.1 to 1g/L, the ratio 
of USP to DSP costs drops from 55:45 to 30:70 [38]. At higher product titer, larger 
chromatography columns, membrane areas, buffer consumption and/or additional chromatography 
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or filtration cycles would be required to purify the cell culture harvest from upstream. Experience 
in the industry shows (which is simulated in our case study later in this chapter) that the overall 
cost per gram of drug substance  purified initially decreases as titer increases; however, the cost 
plateaus as the titer increases further.  In a higher titer process, the increase in downstream cost 
can potentially negate the gains in titer, or overall process throughput. 
 
Given the strong competition in the pharmaceutical industry, the entry of biosimilars into the 
market, combined with the recent changes in the U.S. healthcare system, the ultimate success for 
monoclonal antibody process development will be driven by the ability to produce a high 
throughput and cost-effective process [34, 40].  While there have been a number of efforts trying 
to increase production capacity by increasing cell culture titer, the industry has also been exploring 
strategies to reduce the cost of goods by optimizing downstream processing. Strategies such as 
increasing downstream yield, membrane or resin reuse, chromatography or membrane loading 
capacity, as well as decreasing cycle time and buffer consumption have been utilized to improve 
throughput, reduce raw material and consumable usage,  shorten processing time, and ultimately 
achieve a lower downstream cost of goods. Under compressed drug development time scales, it is 
important for companies to effectively prioritize their strategies to accelerate the process 
development timeline, and thus achieving a competitive advantage. 
 
This chapter specifically focuses on reducing the downstream cost of goods, which is defined by 
the downstream cost per unit of drug substance, through optimizing the purification process. 
Building on our prior modeling work in pharmaceutical manufacturing [41 – 44], we propose a 
systematic decision-making framework that (i) utilizes Design of Experiments (DoE) in 
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conjunction with Principal Component Analysis (PCA) to identify and verify downstream process 
parameters that impact the downstream cost of goods, and (ii) predicts the economic outcome of 




Fig 2.1 Systematic approach to facilitate decision making during monoclonal antibody process 





2.2.1. Monoclonal Antibody Production Process 
 
An example of a typical monoclonal antibody production process is depicted in Figure 2.2. The 
process consists of an upstream process section (USP) and a downstream process section (DSP). 
While the USP includes inoculation, cell culture and primary recovery, the DSP consists of Protein 
A chromatography, followed by two ion exchange steps (flowthrough and bind-and-elute), virus 
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filtration and ultrafiltration and diafiltration. The downstream purification train is designed to 
capture the antibody, reduce impurities, such as aggregates, host cell protein, DNA, leached 




Fig 2.2 Typical monoclonal antibody manufacturing process 
 
 
2.2.2. Process Simulation Software – SuperPro 
 
A process simulation tool such as SuperPro Designer Version 9.0, Build 9, Special Build 2200 
(Intelligen, Scotch Plains, NJ http://www.intelligen.com/) has the capability of integrating both 
process and business modeling functions to facilitate strategic decision making during process 
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development and large scale manufacturing. Some might attempt to model the cost of goods using 
excel. However, since changing in one parameter will cascade the impact on multiple parameters 
downstream, and SuperPro is more efficient to capture this impact compared to excel. Input to this 
tool includes a detailed description of the process steps, and their related costs, such as capital 
investment, total spending in infrastructure, labor and raw material costs.  
 
Figure 2.3 shows the SuperPro model that we use in this study. The model consists of the major 
process steps shown in Fig 2.2, and the associated steps, such as sterile filtration, buffer exchange 
and media prep. The parameter values, raw material and facility costs used in building this model 
derived from literature and process experience. The resulting throughput and cost models 
generated can then be utilized to estimate the final unit cost of drug substance or drug product 








Fig 2.3 Monoclonal Antibody Production Process Flowsheet 
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2.2.3. Design of Experiment (DoE) 
 
A design of experiments approach was taken to explore the impact of selected parameters on the 
downstream cost of goods. Compared to a One Factor at A Time (OFAT) approach, which can 
become very cumbersome when there are more parameters (typically > 2), DoE is more efficient 
in understanding the effect of parameters, their interactions, and generating a predictive model 
with a minimum number of experiments.  
 
Table 2.1 shows the six parameters studied in our DoE. These parameters can potentially reduce 
the downstream cost of goods by increasing the throughputs (yield) or decrease the consumable 
cost (loading). The current process ranges are ranges typically experienced in early phase process 
development, while the optimized range represent the reasonable target ranges after further 
optimization. This DoE study encompasses both the current and optimized ranges and is designed 
to explore whether the changes in parameters within these ranges have a statistical significant 
impact on downstream COGs. A central composite design was utilized in this DoE study and a 










Table 2.1 Parameters and associated ranges for DoE Study 
 
An R-sq value of greater than 95% is required to establish the validity of the DoE model. A P-
value of < 0.05 is required to indicate statistical significance. 
 
2.2.4. Principal Component Analysis 
 
To further verify the conclusions derived from the DoE analysis, the same set of data were 
processed using principal component analysis (PCA) [45]. PCA is a statistical tool that converts a 
set of possibly correlated variables into a set of values of linearly uncorrelated variables called 
principal components (PC). The first PC captures the largest part of variance in the data, the second 
PC the next largest, and so on. The result of PCA is displayed as loading plots, showing 
contributions from original variables [45]. 
 
 
Parameters Current Process Range Optimized Process Range 
Throughput 
Protein A Yield (%) 75 + 5 85 + 5 
IEX I Yield (%) 85 + 5 95 + 5 
IEX II Yield (%) 80 + 5 90 + 5 
Cost 
Protein A Loading 
 (g mAb/g resin) 30 + 3 42 + 3 
IEX I Loading 
 (g mAb/g resin) 200 + 10 250 + 10 
IEX II Loading 
 (g mAb/g resin) 30 + 3 50 + 3 
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2.2.5. Monte Carlo Simulation 
 
Since there are inherent uncertainties in large scale bioprocess production, it is important to 
account for these uncertainties during process modeling for representative results.  The key sources 
of technical uncertainties affecting the biomanufacturing often arise from cell culture titer, 
chromatography loading, yields and process cycle time [46]. Stochastic modeling with Monte 
Carlo simulation was utilized in this case study to understand the output distribution of 
downstream COGs, by incorporating the effect of uncertainties in process parameters. The details 
of our Monte Carlo approach are described below. 
 
 
2.3. Case Study 
 
2.3.1. Overview of the study 
 
A simulation case study is set up to compare the different DSP optimization strategies for high 
titer (1 - 7g/L) process. Typically, during 2nd generation process development, or post approval 
process optimization, efforts are devoted to improve cell culture titer, and ultimately to increase 
production capacity, and improve process economic.  
 
In this case study, we first examine the impact of titer on the overall cost of drug substance through 
Monte Carlo simulation. Previous research has suggested that the high purification cost can 
sometimes negate the benefits gained from the increase in titer and throughput [17]. Hence, to 
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reduce the downstream purification cost for higher titer process, we first identify a list of 
parameters that may have potential impact on downstream cost of goods, then rank them based on 
previous process knowledge. Finally, we have identified 6 parameters to carry forward in our study 
(Table 2.1). These parameters, such as chromatographic yield and loading, could reduce the 
downstream COGs by increasing throughput and reducing the raw material and consumable 
consumption.  
 
When prioritizing development efforts under compressed timelines, it is advantageous to select 
strategies that can maximize the reduction of downstream COGs. A Design of Experiments (DoE) 
approach is utilized to explore the impact of selected parameters on downstream COGs and 
identify statistically significant parameters on COGs.  To further confirm and refine our 
conclusions from the DoE study, Principal Component Analysis (PCA) is used as an alternative 
method to understand the contribution of each parameter to the change in downstream COGs. 
Finally, for the top parameters selected to pursue forward, Monte Carlo simulation is performed 
to evaluate the frequency distribution of downstream COGs by incorporating process uncertainties 
and variability. This systematic approach help prioritize strategies to reduce downstream COGs.  
 
2.3.2. Key Assumptions 
 
There are several key assumptions made in the DoE and Monte Carlo simulations: 
(1) The cost of upstream process is assumed to be independent of titer, although the upstream cost 
can sometimes vary depend on the feeding strategy and culture duration at different titers. In this 
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paper, we focus on identifying strategies to reduce the downstream cost, which is unlikely to be 
impacted by the upstream cost.   
(2) The number of chromatography cycle is fixed in this case study, and the facility is assumed to 
have the flexibility to adjust the column size depending on the incoming streams.  
(3) While some companies continue to manufacture the 2nd generation process at the original 
commercial site, other might move to a different site due to facility fit, cost and other business and 
strategic reasons. Here, we are assuming that 2nd generation process is manufactured at a new 





2.3.3.1. Monte Carlo Simulation Results at Current Downstream Operating Conditions 
 
In order to account for the uncertainties inherent in large scale biomanufacturing, representative 
triangle distributions of the current operating range indicated in Table 1 are assigned to the six 
parameters: Protein A loading, IEX I loading, IEX II loading, Protein A yield, IEX I yield and IEX 
II yield. The base value represents the most likely value, bounded by the maximum and minimum 
values, which are formed by taking into account process fluctuations.  
 
The triangular distribution is derived based on data from manufacturing, pilot and laboratory scale. 
Triangular distribution is also what we typically experienced across various monoclonal antibody 
programs, and is used in an antibody cost analysis by Farid et al [34]. The range for cell culture 
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titer in this study ranges from 0.5g/L to 7g/L, and a uniform distribution is used to ensure that all 
titer set points within the range were simulated with equal probabilities. A total of 300 simulations 
are performed and the simulated cost per gram of drug substance at different titers is shown in 




Fig 2.4 Impact of titer on the overall cost per gram of drug substance 
 
 
Initially as titer increases from 0.5g/L to 2g/L, the cost per gram of drug substance drops from 
$700g/L to $ 200g/L, or a 3.5 fold reduction. However, as the titer increases further beyond 2g/L, 
the cost per gram of drug substance plateaus – minimal to no change is observed with the increase 
in titer. At lower titers of 0.5 – 2g/L, the production cost of antibody is more dominant and 
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therefore maximizing the throughput by increasing the titer is generally an efficient strategy to 
decrease cost of goods [4].  
 
However, at titers greater than 2g/L, larger chromatography columns, which translate into larger 
resin and buffer consumption, larger membrane areas or possibly longer processing time, would 
be required to accommodate for the increased amount of antibody coming from upstream. 
Although the throughput continues to increase with titer, the purification cost increases at a much 
faster rate that it negates the gains from the increase in throughput. As a result, improvement in 
downstream efficiency, either by increase throughput, decrease operation cost or a combination of 
both, could further reduce the downstream COGs.  
 
 
2.3.3.2. Design of Experiments to explore the impact of selected DSP parameters on downstream 
cost of goods 
 
A central composite response surface is used to explore the effect of selected chromatographic 
parameters on downstream COGs at a titer range of 0.5 – 7g/L. For all DoE models generated, the 
R-sq values are greater than 95%, indicating the validity of the model. Table 2.2 displays the p-
values of each parameter at the selected titer (0.5g/L, 2.0g/L, 4.0g/L and 7.0g/L). At 0.5g/L, all 
parameters have been shown to be statistically significant, as they all have p-values of less than 




Compared to the IEX I loading, all other parameters have more significant effect as they have 
much lower p-values. At higher titers of 2g/L, 4g/L and 7g/L, the IEX I loading is no longer 
statistically significant while the other parameters continue to have p-values of < 0.0001 and thus 
statistically significant. IEX I loading has the least to none statistical significance because ion 
exchange resin is relatively inexpensive compared to Protein A resin. In addition, in this case 
study, since the IEX I step is operated in flowthrough mode, the resin already has a high resin 
utilization rate of ~ 200 g/L loading, any further increase in IEX I loading would only result in a 
marginal impact on downstream COGs.  
 
Although the DoE analysis in this study is able to screen statistically significant parameters, it 
doesn’t give insight into the relative importance of these parameters as they all have the same p-
values of < 0.0001. Additional analysis, such as PCA, would be helpful to elucidate the relative 
importance of each parameter on reducing downstream cost of goods. Since PCA is commonly 
used to reduce dimensionality of dataset, the results from the PCA analysis would enable us to 
rank the statistically significant parameters from the DoE study, and thus to identify the top 
parameters for further optimization. Theoretically, we could have optimized all parameters to the 
optimized range, or to some extend beyond the current range, instead of selecting only the top 
parameters for further optimization. However, the former approach is rather time and resource 
intensive, as it would take a series of experiments to identify the appropriate ranges for the 
associated parameters to accompany the change of our main parameters. In addition, every change 
in the process would require subsequent process characterization and validation to justify the 







0.5 2.0 4.0 7.0 
Protein A Yield < 0.0001 < 0.0001 < 0.0001 < 0.0001 
IEX I Yield < 0.0001 < 0.0001 < 0.0001 < 0.0001 
IEX II Yield < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Protein A Loading < 0.0001 < 0.0001 < 0.0001 < 0.0001 
IEX I Loading 0.0303 0.5921 0.4748 0.5131 
IEX II Loading < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Table 2.2 P-values from DoE Analysis 
 
2.3.3.3. Principal Component Analysis to confirm or refine DoE results 
 
In order to verify and further refine the conclusions derived from the DoE analysis, the DoE data 
are processed through PCA. The first principal component captures ~ 30% of the total variance in 
the downstream cost of goods. The loading plot (Figure 2.5) from the first principal component 
confirmed that at all titers analyzed, the IEX loadings have lower contributions to the downstream 
cost of goods compared to chromatographic yields or protein A loading. As discussed in 
previously, IEX resin in general is less costly, therefore increasing the resin utilization is unlikely 





Fig 2.5 Loading plot from PCA analysis 
 
 
The loading plot shows that at 0.5g/L, IEX II yield has the biggest contribution to the total variance. 
Furthermore, the chromatographic yields (ProA yield, IEX I yield and IEX II yield) have higher 
loading scores, or bigger contribution, compared to chromatographic loading (ProA loading, IEX 
I loading and IEX II loading). This trend indeed  aligns with what have been shown in previous 
literature research that at a lower titer, especially at < 1.0g/L, the purification cost is relatively 
lower [17]. Thus, increasing the overall throughput is a more competitive strategy to reduce cost.  
 
At higher titers of > 2g/L, protein A loading has the most influence on the downstream cost of 
goods; more importantly, its contribution to the total variance increases as the titer increases. The 
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cost of Protein A resin becomes more significant as titer increases, because more resin would be 
needed to purify the incoming stream, given the number of chromatography cycle is fixed in this 
study.  The cost of this highly expensive resin is indeed ~ 85% of the total consumable cost at 7g/L 
titer. Hence, an increase in Protein A loading would increase the resin utilization and therefore 
decrease the total amount of Protein A resin consumption. 
 
In addition, the loading plot shows the intra-relationship of parameters. For instance, as titer 
increases, the contribution of chromatographic yields (ProA yields, IEX I and II yield) decreases, 
while the contribution of chromatographic loading (ProA loading and IEX II loading) increases. 
This implies that the purification cost becomes more dominant at higher titer. Reduction in resin 
consumption, especially the protein A resin, is likely to decrease the downstream COGs 
significantly.  
 
This case study, along with scientific justification, suggests that both Protein A loading and IEX 
II yield have the most influence on the downstream cost of goods. Monte Carlo simulation is 
utilized to generate the frequency distribution of downstream COGs by optimizing either the 
Protein A loading or the IEX II yield and the results are compared with the average downstream 








Similar to the Monte Carlo simulation set-up in the previous section, representative triangular 
distributions indicated in Table 2.3 are assigned to the six key downstream parameters and titer. 
The fluctuations in these parameters are typically observed in large scale manufacturing.  
Three hundred simulations are performed and Figure 2.6 shows the downstream COGs frequency 
distributions for (1) base case, in which all parameters are set at current process conditions, (2) 
Optimized Protein A Loading, in which the Protein A loading is operated at target condition while 
the other parameters remain constant, and (3) Optimized IEX II Yield, in which the IEX II yield 
is operated at target condition while the other parameters remained constant. Protein A loading 
and IEX II yield are chosen for further study because of their strong contribution to the variance 
in downstream COGs through the PCA analysis.  
 
At a lower titer of 0.5g/L, the frequency distribution of the downstream COGs is positively skewed 
at both optimized conditions, although the mean is slightly lower when the IEX II yield is 
optimized. At 2g/L, in the base case, the downstream COGs span from $47.5/g to $70/g , whereas 
the cost distribution is much narrower in the optimized cases: with a range of $40/g – $57.5/g when 







Fig 2.6 Frequency distribution for downstream cost of goods of base case and optimized conditions 
 
 
In addition, compared to the base case, increase in IEX II yield reduces the mean downstream 
COGs by 11%, while a 14% reduction is achieved by increasing the Protein A loading. This 
observation confirms our previous conclusion that Protein A loading is more significant than IEX 
II yield in terms of their impact on downstream COGs.  
 
As the titer increases to 7g/L, the mean downstream COGs is reduced by almost 20% at the 
optimized Protein A loading condition while 15% reduction is achieved at optimized IEX II yield. 
Moreover, the “risk,” which is measured by the standard deviation, is lower at the optimized 






Table 2.3 Parameters and associated ranges for Monte Carlo Simulation 
 
 
While the more traditional approach to estimate the average downstream COGs at optimized 
conditions is often a deterministic estimation, a stochastic approach with Monte Carlo simulation 
can sometimes offer a more accurate estimation for processes that are inherently random [42]. 
Figure 2.7 shows the cumulative probability plots of the downstream COGs for different process 
conditions, and the black line indicates the average downstream COGs obtained by deterministic 
approach. At 0.5g/L, the deterministic estimates are close to the expected mean from the Monte 
Carlo simulation in all three conditions. However, as titer increases to 2.0g/L, about 70% of the 
population is below the deterministic estimate with optimized Protein A loading, while 80% of the 
population is above the with optimized IEX II yield.  
Hence, predicting the downstream COGs using a deterministic approach can sometimes 
overestimate or underestimate the mean, consequently distorting the ranking of parameters. The 
comparison between the two approaches at 7g/L titer further emphasizes the limitation of the 
 52 
 
deterministic approach. The deterministic analysis suggests that optimizing IEX II yield is more 
effective, as indicated by lower expected downstream COGs, contradicting the conclusion from 
the PCA analysis.  
 
Monte Carlos simulation results suggest that the most of the population is below the deterministic 
mean in the case of optimized Protein A loading, whereas most of the population is above the 
deterministic mean in the case of optimized IEX II yield. These results highlight the drawback of 











This chapter provides a systematic framework to identify parameters that have the most impact on 
downstream costs of goods, and ultimately facilitate strategic decision making during process 
optimization for monoclonal antibody production. A design of experiments approach enables a 
screening of statistically significant parameters, based on the p-values.  
 
Further analyzing the DoE data through principal component analysis confirms the conclusion 
from the DoE study and, more importantly, offers insights on the relative contribution of each 
parameter to downstream of goods. Finally, a stochastic simulation is utilized to generate the 
frequency distribution of the downstream cost of goods by incorporating the process uncertainty.  
Although there are only 6 parameters in our study, this is intended to serve as an example of how 
we can implement DoE-PCA and Monte Carlo simulation to enable decision making during 2nd 
generation process development. In other cases, there might be more parameters, and this approach 
can systematically identify strategies that can maximize the cost reduction under a compressed 
process development timeline. 
 
Process optimization has been utilized in various stages of drug development, such as pre and post 
drug approval, to increase flexibility and decrease production cost. In addition to control the cost 
through process optimization, another approach the industry uses is to minimize product failure 










The pharmaceutical and biotechnology industry face unprecedented challenges and competition 
due to the expiration of blockbuster drugs, shorter time-to-market, declining in R&D productivity 
and stringent regulatory requirements. The entry of generic drugs accounts for substantial loss of 
market shares for brand-name manufacturers, significantly impacting the financial resources for 
R&D activities [47]. Zantac, a brand-name product, experienced a price erosion of 90% within 2 
years after the generic version entered to the market [48]. While the industry is striving to increase 
its pipeline to recoup the loss from patent expiration, many companies are also restructuring their 
R&D to increase efficiency and reduce operational cost.  
Merger and acquisition is one strategy that larger companies use to acquire the pipeline of the other 
companies. For example, Sanofi expanded its biologics pipeline by acquiring Genzyme. Similarly, 
the acquisition of Pharmasset accelerated Gilead’s development of the Hepatitis C virus (HCV) 
franchise. One of the products from Pharmasset has become a blockbuster drug, Sovaldi, which 
represents a large portion of Gilead’s revenue. In addition to merger and acquisition, 
pharmaceutical and biotech companies have started to outsource part of their basic discovery, 
preclinical animal studies or clinical pharmacology studies to contract research organization [48].  
 
While R&D is undergoing restructuring, a lot of attention also focuses on manufacturing. 
According to estimates, the manufacturing costs can be as high as 27-30% of sales for 
manufacturers of brand name pharmaceuticals [35, 36, 49], and more than double the share of costs 
for research and development [35, 36]. In an effort to reduce manufacturing cost, some approaches 
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aim at optimizing and streamlining the manufacturing process to reduce the cost of goods, while 
other approaches focus on ensuring process and quality consistency, and ultimately minimizing 
process deviation and batch failures.  
 
For the latter, routine, ongoing assessment of process performance and product quality is critical 
to ensure process consistency, and most importantly, to ensure high quality pharmaceuticals reach 
patients in timeline manner [50]. Prior to transferring a process to commercial scale, critical 
process attributes (CPA) and critical quality attributes (CQA) are selected through a quality by 
design (QbD) process. During the production of each batch, statistical tools such as Shewart 
control chart, are used to monitor these CPAs and CQAs, ensuring that they are within the 
predetermined process control limits.  
 
In addition to monitoring the current performance, the ability to predict the performance of future 
batches is very critical. If we suspect any systemic deviation or shortage of drug production, 
mitigation strategies can be developed in advance to minimize the risk. Although advanced 
quantitative methods, mathematical and statistical models have been in used in various aspects of 
pharmaceutical drug development and manufacturing, such as clinical [8] and product quality risk 
quantification [9], application of such tools in predicting drug manufacturing performance is yet 
to be developed.  
 
The conventional approach, or the approach that is widely used in the industry, for predicting batch 
performance usually assumes the mean of the upcoming batch is equal to the mean of the historical 
batches. While this approach can give a reliable estimation when the all batches perform very 
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consistently, it might not be sensitive to subtle changes in certain batches, especially when the 
sample size of the historical data is much larger than that of the recent data. The Bayesian 
approach, however, offers a rigorous way to quantify prior information and combine it with recent 
data to obtain a prediction for upcoming batches.  
 
Building on our prior modeling work in pharmaceutical manufacturing [41, 42, 43, 44], we propose 
a framework that compares the application of the conventional and Bayesian approach to predict 
drug manufacturing performance. Although Bayesian statistics has been often used in clinical 
studies and simulation, there is little development of such application in the pharmaceutical 
manufacturing setting.  Furthermore, this chapter also discusses tools to determine when Bayesian 
is more appropriate than the conventional approach, and finally discuss the limitation for the 
Bayesian approach.  
 
 
3.2. Methodology  
 
This chapter discusses the use of a conventional and Bayesian approach for parameter prediction 
in the context of monoclonal antibody (mAb) manufacturing. Prior to transferring the production 
process to commercial scale, CPAs and CQAs are identified through process characterization 
studies.  
 
According to the ICH (International Council on Harmonization of Technical Requirement for 
Registration of Pharmaceuticals for Human Use) guideline, CPAs are process related attributes, 
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physical, and CQAs are physical, chemical, biological or microbiological property or 
characteristics that should be within an appropriate limit, range, or distribution to ensure process 
consistency and desired product quality, respectively.  
 
Typically, CPAs and CQAs can be identified based on the severity of harm to process consistency 
or to a patient (safety and efficacy) resulting from failure to meet that attributes. In a biologics 
manufacturing process, typical CPAs include titer and yield, and typical CQAs include impurity 
level and potency. In our case study, we focus on two attributes in a downstream purification step, 
specifically the Protein A chromatography yield, IEX chromatography yield and Host Cell Protein 




3.2.1. Data Collection 
 
The data from the case study are actual data collected from a monoclonal antibody manufacturing 
process. Both the yield and HCP impurity level data are collected at every cycle, and there are 
about 5 – 6 cycles per batch in this process. All data have been validated by internal quality control 
group. In addition, the datasets are screened for potential outliers, and they would be excluded 
only if there is sufficient rationale to support the exclusion of such data points. These data are 
scaled for confidentiality purposes, but the general trends are preserved. 




Figure 3.1 shows the set- up of the conventional and Bayesian approaches to predict the mean of 
the upcoming batch. The older and recent batches are used as a training dataset, while the most 
recent batch is treated as a test dataset. The goal was to evaluate how comparable the predicted 








For the conventional approach, or the approach that’s widely practiced in the industry, the 
predicted mean is believed to be approximately the mean of all the batches conducted thus far, or 
the overall mean of the training dataset, and the standard deviation of the mean is computed as the 
observed standard deviation divided by the sample size. While this approach is relatively 
straightforward, there are several incidences where this approach might not be able to offer a 




For example, if the historical dataset is much larger than the recent dataset, any subtle changes or 
systemic deviation, caused by shift in operation, raw material or other factors, in the recent batches 
would not be able to be reflected in the mean. The Bayesian approach, however, offers a more 
reliable way of estimating the mean by leveraging information from historical batches and 
capturing changes from recent batches.  
 
The Bayesian posterior probability is defined as the follows: 
 
 
p(θ│x)=  (p(x│θ)p(θ))/(p(x))                                                                                    (3.1) 
 
 
The posterior probability given the evidence x, p(θ│x), is equal to the likelihood function, or the 
probability of the evidence given the parameters, p(x│θ) , times the prior probability, p(θ) , 
normalized by the probability of evidence x , p(x). In our case, prior distribution is derived from 
the historical data and the likelihood was derived from the recent dataset, and we use the new 
information from the recent dataset to update our prior knowledge of the process.  
 
Figure 3.2 shows the process of generating the different distributions. We first gather the 
appropriate data, and then determine the distribution based on the data collected. Usually a 
biological process follows a normal distribution because the process is tightly controlled at a 
manufacturing setting, and the data tend to center at the mean.  After identifying a distribution, it 
is crucial that we validate it. For instance, if we hypothesize that a dataset follows a normal 
distribution, a normality test should be conducted to verify it. After the validation, we would then 
extract the key parameters, such as mean and standard distribution in the case of a normal 




Fig 3.2 Overview of Probability Distribution Generation Process 
 
 
In most cases, we derive the prior distribution from historical manufacturing data. Based on 
previous process experience and consultation with subject matter experts, we derive the prior 
distribution from a minimum of 25 cycles, or 5 batches. This should be sufficient to give a reliable 
and representative prior distribution, unless the data are highly variable, in which case more data 
would be needed to generate the prior distribution. In the case where there aren’t enough historical 
data, we would need to gather data from experiments performed at the laboratory or pilot scale to 
have a large enough dataset to derive a prior distribution.  
 
However, since the latter dataset are generated at a smaller scale compared to the manufacturing 
scale, poolability test such as one way analysis of variance (ANOVA) needs to be conducted to 
ensure the smaller scale data are representative of the manufacturing scale data, since our ultimate 
objective is to predict the batch performance at manufacturing scale.  
 
The likelihood distribution is typically generated from the data of the most recent batch, because 
we believe that any systematic change occurs in this batch is likely to be carried onto the 
subsequent batch. Although there are numerous ways to leverage the manufacturing data to 
generate the likelihood distribution, we chose only the most recent batch because we wanted to 
capture any change from this recent batch to predict the performance of the subsequent batch. In 
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our case study, since we use the most recent batch as the test dataset, we form the likelihood 
distribution from the 2nd to the most recent batch.  
 
With the process knowledge and consultation with subject matter experts in the field, the CPA and 
CQA of this process, similar to other manufacturing processes, follow a normal distribution. To 
verify the validity of this assumption, a normality test, such as Anderson – Darling statistics, which 
measures how well the data follow a normal distribution, was conducted using Minitab.  
For a normal distribution, the two key parameters are mean and standard deviation. In terms of the 
likelihood distribution, the mean and standard deviation are simply those of the most recent batch. 
For the prior distribution, the prior mean is initially calculated as the mean of the historical batches 
and the standard deviation of the mean is calculated as the observed standard deviation divided by 
the sample size. As a result, the standard deviation decreases as the sample size of the historical 
data increases.  
 
The posterior mean is a weighted average of the prior mean and the likelihood mean, with the 
weight inversely proportional to the standard deviation of the prior mean and the standard 
deviation of the likelihood data. Hence, as the standard deviation or the uncertainty of the prior 
mean decreases, the posterior mean would be heavily dominated by the prior mean. Similar to the 
results from the conventional approach, the heterogeneity between the prior and likelihood became 
diminished in the posterior mean.  
To address this issue, Ibrahim and Chen [51] proposed the concept of the power prior, based on 
the notion of the availability of historical or prior data. The power parameter, with (0 < δ < 1), will 
dictate how much historical data information are to be used in the analysis. However, in their 
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approach, the power parameter has a tendency to be close to zero. In other words, much of the 
historical data would not be used in predicting the mean [52].  
 
Here, we propose a different approach in deriving the prior standard deviation, such that the 
predicted mean is not overwhelmed by the historical data due to the large sample size. Instead of 
using the overall observed standard deviation divided by the square root of the sample size of the 
historical data, we first calculate the standard deviation of the mean for each batch, and the prior 




𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑎𝑛𝑃𝑟𝑖𝑜𝑟 =  
∑ 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑎𝑛𝑏𝑎𝑡𝑐ℎ 𝑖
𝐵𝑎𝑡𝑐ℎ
𝑖 = 1
𝑁𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑎𝑡𝑐ℎ𝑒𝑠
                   (3.2) 
 
 
Based on this formula, the standard deviation of mean is indeed the average standard deviation 
with respect to the number of batches, instead of number of cycles. Since our goal is to estimate 
the mean for the upcoming batch, it is reasonable to calculate the average standard deviation of 
the mean per batch instead of per cycle. With this approach, the standard deviation of prior 
distribution would be less likely to be affected by the size of the historical dataset. Hence, the 
prediction would be less likely to be overwhelmed by the prior mean.  
After establishing the key parameters, a simulation is conducted to derive the posterior probability 
(Eq. 3.1) against a range of relevant process set points, which are typically the minimum and the 
maximum of the manufacturing range. In addition, the predicted mean and their range from both 
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approaches are compared to the actual mean. The difference between the predicted and the actual 





3.3.1. Conventional and Bayesian Approaches Result in Different Predicted Means 
 
With the emergence of process analytical tools (PAT) as well as other data acquisition tools, 
process and product quality data become readily available. Therewith, it is critical to have a reliable 
computational tool to monitor and predict process performance, by leveraging available data.  
 
Figure 3.3 is a statistical process control diagram of Protein A chromatography yields. The older 
batches, which consist of 34 cycles, have higher yield than the recent batch, which has 6 cycles. 
The change in the yield is due to the replacement of chromatography resins. Ideally, a predicting 
tool would be able to incorporate information from both the older and recent batches when 





Fig 3.3 Statistical Process Control Diagram of Protein A Chromatography Yield 
 
 
Figure 3.4 shows the probability distribution of the mean for different datasets, prior, likelihood, 
predicted means by the conventional and Bayesian approach. Table 3.1(dataset 1) also shows the 
predicted mean, their respective confidence interval and the actual mean.  
 










(75.1 – 82.0) 
83.6 
(81.0 – 86.2) 
Actual Mean: 77.3 (74.2 – 80.4) 
2 1.08 
86.4 
(82.9 – 90.0) 
86.7 
(84.1 – 89.4) 
Actual Mean: 84.2 (82.1 – 86.3) 
                             Table 3.1 Impact of the Mean Ratio on the Predicted Means 
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The conventional predicted mean is dominated by the prior mean, and overestimates the actual 
mean for the upcoming batch. In fact, with the conventional approach, as the number of historical 
batches increased, the historical data would dominate the mean and the heterogeneity between the 
historical and recent batch would have less impact on the predicted mean. Consequently, this 
approach may result in misleading conclusions, especially where there is a systemic deviation from 
historical batches.  
 
 
Fig 3.4 Probability Distribution of Prior, Likelihood and Predicted Means of Protein A 
Chromatography Yield with Bayesian Approach 
 
 
However, the Bayesian predicted mean falls between the prior and the likelihood mean, and more 
importantly, it accurately predicts the test mean. Hence, if a systemic deviation is suspected in a 
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process, this modified Bayesian approach would be likely to offer a more accurate estimate than 
he conventional approach, as the Bayesian approach is better at capturing the heterogeneity 
between the prior and likelihood and less sensitive to the sample size of the prior dataset.  
 
To test the robustness of this conclusion, we have applied both approaches in other attributes, in 
other processes, such as IEX yield (figures 3.5 and 3.6). Similar to the conclusions that we arrive 
with the Protein A yield, the Bayesian approach offers a more reliable estimate than the 
conventional approach in cases whether there are subtle changes in recent batches. 
  
 
Fig 3.5 Statistical Process Control Diagram of IEX Chromatography Yield. Blue diamonds represent 








Fig 3.6 Probability Distribution of Prior, Likelihood and Predicted Means of IEX Chromatography 




3.3.2. Prior and likelihood mean ratio vs Bayesian predicted mean 
 
To quantify the heterogeneity between the prior and likelihood mean, ratio between the prior and 
likelihood mean is determined [51]. Here, we analyze two sets of protein A chromatography yield 
data. In one of them, the prior and likelihood come from the same population, whereas in the other 




Table 3.1 shows the summary of these two sets of data: their mean ratio, predicted mean, the 
corresponding confidence interval and the actual mean. In the case where both the likelihood and 
prior come from the same population, or the mean ratio is close to unity, both the conventional and 
Bayesian results in similar predicted mean. 
 
Although the Bayesian predicted mean is a weighted average between the prior and the likelihood, 
when both of these distributions have similar means, the Bayesian predicted mean is similar to the 
overall mean. Hence, the two approaches result in a similar estimation.  
 
However, as the heterogeneity between the prior and likelihood distributions increases, or the ratio 
of the two means moves away from unity, the predicted means and their 95% confidence interval 
by the two approaches start to deviate. As mentioned in previous sections, in the case where there 
is more prior data compared to the likelihood data, the Bayesian approach is more sensitive at 
capturing the heterogeneity between the two distributions. Therefore, while the conventional 
predicted mean is dominated by the prior mean, the Bayesian predicted mean would have the 
contributions from both the prior and likelihood distributions.  
 
Based on the results from this study, the mean ratio can be used as a tool to determine whether 
Bayesian is needed for a particular analysis. If the mean ratio is close to unity, or the prior and 
likelihood distributions come from the same population, then the two approaches should result in 
similar predicted means. However, as the mean ratio deviates from unity, or there is heterogeneity 
between the prior and likelihood mean, then Bayesian would be better at capturing this 
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3.3.3. Impact of uncertainty in likelihood data on Bayesian predicted mean 
 
Our previous analysis suggests that when there is heterogeneity between the historical and current 
data, Bayesian, compared to the conventional approach, is better at capturing the heterogeneity 
and thus offering a more accurate prediction of the future batch. However, it is important to note 
that the Bayesian posterior mean is a weighted average of the prior mean and the observed data, 
with the weighting corresponding to the relative precisions of the prior and the likelihood. 
Therefore, when the prior is highly precise compared to the likelihood, the prior is weighted 





Fig 3.7 Statistical Process Control Diagram of HCP Impurity Level in Protein A Eluate 
 
 
Figure 3.7 shows the host cell protein impurity level in the Protein A chromatography eluate. 
Similar to the Bayesian analysis conducted for the Protein A chromatography yield, the older 
batches are used to form the prior distribution, the more recent batch is used to form the likelihood 
distribution and the most recent batch is used as a test dataset.  
 
As shown in Figure 3.8, since we switched the testing assay, the prior distribution appears to be 
much tighter than the likelihood distribution, and hence the posterior distribution of the mean is 
dominated by the prior mean. In this case, although there is heterogeneity (mean ratio = 0.66) 
between the historical and the current data, the Bayesian approach was not able to capture it and 
the predicted mean underestimates the actual mean.  
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The results from this analysis suggest that a low precision of the observed data can be a limitation 
to the Bayesian approach. One way to overcome this limitation includes using the same or similar 















3.4. Summary and Conclusion 
 
In this chapter, both the conventional and the Bayesian approaches are used to predict the 
performance of an upcoming manufacturing batch, by leveraging the data from historical batches. 
Although the conventional approach is easier to implement, it might not be sensitive enough to 
capture the heterogeneity between historical and current batches. For instance, when the sample 
size of the historical data is much larger than the current data, the heterogeneity between these two 
is diminished, because the predicted mean is largely dominated by the historical mean. Therefore, 
in the case where there is a systemic deviation, this approach is less likely to result in an accurate 
prediction of the upcoming batch. 
 
Compared to the conventional method, Bayesian is shown to be often better at capturing the 
difference between the historical and current data, and is therefore able to make better predictions. 
When using the Bayesian approach, it is important to note that the posterior mean is a weighted 
average of the prior mean and the likelihood mean, with the weight inversely proportional to the 
standard deviations of the prior and likelihood data. Hence, as the standard deviation of the prior 
mean decreases, due to large sample size, the posterior mean would be heavily dominated by the 
prior mean.  
 
Therefore, in the calculation of the prior standard deviation, we do not just take the overall standard 
deviation of all data, which can be heavily affected by sample size. Instead, we first calculate the 
standard deviation of the mean for each batch, and the prior standard deviation of the mean would 
be the average of the standard deviation per batch. As shown in our analysis, this approach 
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circumvents the issue of the predicted man being overpowered by the historical mean. The 
predicted mean is indeed comparable to the actual mean.  
 
While Bayesian is better at capturing the heterogeneity than the conventional approach, there are 
occasions that both approaches offer the same prediction, especially in the case where the batches 
perform consistently. Here, we present a tool to determine whether a Bayesian approach is 
necessary for a particular analysis. The ratio between the historical and current mean can be used 
to measure process consistency. For instance, as the ratio deviates more and more from unity, then 
Bayesian is likely to be a better approach, as there is inconsistency between historical and current 
batch performance.  
 
As mentioned previously, the Bayesian posterior mean is a weighted average between the 
historical mean and observed data, weighting by the certainty of each distribution. As a result, if 
the current data is much more spread out, or less informative than the prior mean, due to the change 
in assay precision or other factors, then the prior mean would have a larger contribution to the 
posterior mean. This is indeed a limitation to the Bayesian method. To overcome this limitation, it 
is critical to control the precision from batch to batch to ensure a reliable estimation.  
In addition, Bayesian can capture the heterogeneity between the historical and observed data when 
there is a systemic change in the manufacturing process. In other words, the subsequent batch 
should have a similar trend to the current batch and the change in the current batch is systemic but 
not sporadic. Both the uncertainty of the distribution and the nature of process change in the current 
data can limit the accuracy of the Bayesian approach.  
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As the FDA regulations become more stringent, and more data become available with the 
development of advanced data acquisition tools, it is important to leverage available information 
to monitor and predict process performance. Although the Bayesian approach, which is widely 
used in clinical settings, is less frequently used in pharmaceutical manufacturing, it is better at 
capturing process heterogeneity compared to the conventional approach. Therefore, when there is 
a systemic change in the manufacturing process, the Bayesian approach can enable a more accurate 
prediction of future manufacturing performance.  
 
In addition to minimizing batch failure through reliable process monitoring and trending, 
biopharmaceutical companies need to ensure their final drug product meet the predefined 
acceptance criteria, for product safety and efficacy. To meet this goal, biopharmaceutical 
companies need to conduct a series of process characterization and validation studies, to fully 
understand the nature of the manufacturing process, identify critical process parameters and their 
operating range. Furthermore, it is paramount that appropriate immediate product specification is 
set based on process capability and final drug product specification. These intermediate 
specifications will serve as forward processing criteria for each step and ensure a higher likelihood 








4 Neural Network to Understand Process Capability and Process 
Intermediates Acceptance Criteria in Monoclonal Antibody 
Production Process 
 
4.1. Introduction  
Monoclonal antibodies are typically produced by mammalian cell culture in bioreactors that range 
in scale of 1- 20 m3. Regardless of scale, the production and purification of mAb present important 
challenges [18]. Such a complex multistep process, which encompasses several seed and 
production bioreactors, as well as a number of chromatography and filtration steps, needs to be 
carefully monitored and controlled as many of the in-process variables can impact the product 
quality. Recent developments at the FDA recommend the application of risk-based approaches to 
control product quality based on an enhanced process and product understanding [53].  
 
In our previous studies, we established a framework that integrates design of experiments (DoE) 
and principal component analysis (PCA) to identify process parameters that have significant 
impact on critical process attributes [39]. Hence, we can now control the process by ensuring that 
these parameters are operated within the acceptable range, and thus improving process robustness 
and consistency.   
 
Furthermore, since any quality issues in manufacturing will delay the release of a batch and can 
sometimes disrupt the supply chain, we developed a systematic framework to predict future 
manufacturing performance or product quality using a Bayesian approach [54]. Therefore, in cases 
where we suspect a potential deviation in the future manufacturing batches, appropriate mitigation 
strategies can be developed in advance to reduce risks or batch failures.  
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In addition to identifying critical process parameters, and developing a framework to predict drug 
manufacturing process performance, it is very important to have appropriate impurity acceptance 
criteria for process intermediates. In fact, defining the in-process acceptance criteria is part of the 
control strategy, which will eventually go into the drug validation regulatory package.  
 
While there is considerable literature describing the different approaches to define acceptance 
criteria or specification for the final drug substance, which directly links to the clinical efficacy 
and safety [53], the industry is still learning the different ways to set process intermediates 
acceptance criteria. These acceptance criteria lead to a tradeoff between the likelihood a consumer 
will acquire a suboptimal dose and the likelihood a lot will fail release [20]. Although narrower 
acceptance criteria are more likely to ensure a successful batch release, and to achieve pre-defined 
safety and efficacy, it could potentially reject batches that would otherwise have met the final drug 
specification. Hence, it is critical to establish accurate and appropriate acceptance criteria.  
 
While the end goal of drug manufacturing is to meet the final drug specification by having stringent 
control of process intermediates, there are several ways of establishing in-process acceptance 
criteria. A widely used approach is to use the final drug substance or product specification as a 
reference, and deduce the specification for products from previous steps based on the process 
capability of those steps.  
 
For instance, if the final process step has a constant 3% impurity reduction, and if the specification 
for the final product is 2%, then the product of the step before the final step, or the input to the 
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final process step should have impurity level no greater than 5%. However, the difficulty here is 
in knowing what the impurity reduction for each step is. 
 
One approach is to develop a mechanistic model of a specific process, and leverage this model to 
predict the input specification based on the final output specification. However, this approach is 
very process specific, and would involve significant amount of time and effort for model 
development. Hence, this approach is rarely used for acceptance criteria setting.  
 
Another way to understand process capability is to do a worst case scenario study. In such study, 
we challenge the chromatography column or filter with a significant higher than typical amount of 
impurity, and find out the maximum impurity reduction this step can achieve. A challenge with 
this approach is that sometimes it could be difficult to find a feed stream with such a high impurity 
level while ensuring these impurities are representative. In addition, a lot of experiments need to 
be conducted before we are able to reach the saturation point. 
 
Some other simpler approach used in the industry to understand process capability is to compare 
the average impurity levels of the feed and the product, and the average reduction is used to 
calculate the in-process acceptance criteria. While this is relatively straightforward, one caveat is 
that it assumes that the impurity clearance is independent of the feed impurity level. For instance, 
two feeds with different impurity levels are assumed to undergo the same degree of reduction; 
however, this is not always the case, as shown later in our study.   
Building on our prior modeling work in pharmaceutical manufacturing [41, 42, 43 and 44], we 
propose an alternative way to calculate process capability, by using neural network to characterize 
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the relationship between the feed and the product quality attributes of a particular process step. It 
is a promising modeling technique especially for datasets having the kind of non-linear 
relationships that are frequently encountered in pharmaceutical processes.  
 
Contrast to what’s commonly practiced in the industry, we do not have to assume that the impurity 
reduction is independent of the feed. The neural network model can identify and learn correlative 
patterns between feed and product data pairs. Once trained, it may be used to predict the product 
impurity level based on the feed impurity level, or vice versa. One of the most useful properties of 
neural networks is their ability to generalize. 
 
Diagnostic plots will be used to evaluate the goodness of fit before arriving at the final neural 
network model. In addition, we will compare this approach with the conventional approach 
practiced in the industry, and determine if there is any difference in model prediction accuracy. 






4.2.1. Overview of Monoclonal Antibody Production Process 
 
A typical monoclonal antibody production process consists of an upstream process (USP) section 
and a downstream (DSP) process section, as shown in Figure 4.1.  While the USP includes 
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inoculation, cell culture and primary recovery, the DSP consists of Protein A chromatography, 
followed by two ion exchange steps (follow-through and bind-and-elute), virus filtration and 
ultrafiltration. In general, biological molecules are much more complex changes in the production 
process. Therefore, it is imperative to closely monitor the critical quality attributes for process 
intermediates, such as Protein A product (or IEX I feed), or IEX I product (or IEX II feed), to 









In our case study, we focus on the clearance of protein aggregate through various downstream 
chromatography steps. Protein aggregation is a key challenge in the development of protein 
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biotherapeutics. Aggregates are defined as any physically associated or chemically linked non-
native species of two or more protein monomers, as shown in Figure 4.2 [55]. It is widely accepted 
in the scientific literature that protein aggregation can augment a protein-specific immune 
response, and therefore lead to the formation of anti-drug antibodies (ADA) [56,57], which can 
cause adverse events, such as neutralization of endogenous protein or reduce efficacy of a 














The data from the case study are a combination of actual data from several monoclonal antibody 
manufacturing processes and simulated data. All data and simulated models have been validated 
by internal quality control group. These data have been scaled for confidentiality purposes but the 
general trends are preserved.  
 
 
4.2.3. Approach to estimate process capability 
 
4.2.3.1 Conventional Approach 
 
The conventional approach, or what is commonly practiced in the industry, to understand process 
capability, or the impurity reduction of a particular step, is as follow: 
 
 
?̂?𝑝𝑟𝑜𝑑,𝑖 = 𝑌𝑓𝑒𝑒𝑑,𝑖 − ?̅?𝑟𝑒𝑑   
 
 
where the product aggregate level (?̂?𝑝𝑟𝑜𝑑,𝑖) is estimated as the difference between the feed 
aggregate level (𝑌𝑓𝑒𝑒𝑑,𝑖) and the average aggregate reduction (?̅?𝑟𝑒𝑑).  
 
 




Although the conventional method is relatively straightforward, it assumes the impurity reduction 
is constant regardless of the feed impurity level. However, this is not true in all cases. For example, 
protein aggregates usually consist of a mixture of multi-mers, such as dimer, trimer, and other 
higher order multi-mers. The higher order aggregates are usually easier, and the first to be purified 
while dimers are much more challenged to be reduced.  
 
Hence, it is often the case that if the feed stream has a higher level of aggregates, we observe a 
higher percent of aggregate reduction, since most of the higher order aggregates are being 
removed. On the other hand, if the feed stream has very low level of aggregate, which is most 
likely comprised of dimers, the impurity reduction might be much smaller since the dimers are 
difficult to remove. Hence, for the same purification step, impurity clearance could vary based on 
the feed impurity level, and using the conventional estimation method would not be able to reflect 
this phenomenon.  
 
In addition to conventional approach, one might attempt to model the data using higher order of 
polynomials, such as quadratic regression. However, this approach might not be able to describe 
the data appropriately (Appendix Table A7.3.1.1). Furthermore, this approach can involve in a lot 
of trial and errors in order to find the best fit. Hence, here we propose the use of neural network to 
relate the feed impurity level to the product impurity level, such that the product impurity level is 




The neural network models are composed of simple elements operating in parallel. The connection 
between elements largely determines the network function. A neural network can be trained to 
perform a particular function by adjusting the value of the connections (weights) between elements 
[59]. Hence, neural networks are able to recognize patterns even from noisy and complex data in 
which there is a considerable degree of variation and to estimate non-linear relationships [60].  
 
The use of neural networks is an expanding area in the field of pharmaceutical research. Some of 
the important applications are in molecular modeling, pharmacokinetic and pharmacodynamics 
modeling, and in vitro/in vivo correlation [60, 61,62,63,64]. However, the application of neural 
networks in understanding process capability and define process specification is still limited. In 
our study, we develop neural network models to correlate the feed aggregate level with the 
corresponding product aggregate of several chromatography steps.  
 
 
4.2.3.2.1 Neural Network Model Selection and Evaluation 
 
Typically, neural networks are adjusted, or trained, so that a particular input leads to a specific 
output [59]. As shown in Figure 4.3, the network is trained, by comparing the model predicted 
output with the target, until most of the network outputs match the targets. Many such input-target 










In our study, the neural network is trained by backpropagation algorithm, which is the most widely 
used neural network learning method [65]. As shown in Figure 4.4, the input layer communicates 
with the external environment and presents the pattern to the neural network [66]. The hidden layer 
is the collection of neurons which has transfer function (usually sigmoidal function), applied on it, 
as well as provides an intermediate layer between input and output layer [67]. In order to ensure 
the performance of the neural network, it is critical to select an appropriate topology, and two of 
the important governing elements are the training algorithm within the backpropagation family, as 










4.2.3.2.1.1 Training Algorithm  
 
The training algorithm depends on whether the network is being used for pattern classification or 
function approximation. Since we are trying to approximate the correlation between the feed and 
product aggregate, some of the common algorithms are Levenberg-Marquardt (LM), Scaled 
Conjugate Gradient (SCG) and BFGS Quasi-Newton (BFG).  
 
For function approximation problems, LM has the fastest convergence. The performance of BFG 
is similar to that of LM, but it does not require as much storage as LM. However, the computation 
required for BFG increases geometrically with the size of the network. SCG algorithm seems to 
perform well over a wide variety of problems, particularly for networks with a large number of 






4.2.3.2.1.2 Hidden Layer and Nodes 
 
The standard network that is used for function fitting is a two-layer feedforward network, with a 
sigmoid transfer function in the hidden layer and a linear transfer function in the outer layer. Since 
in our study, we have a continuous mapping from one finite space (feed aggregate level) to another 
(product aggregate level), we have chosen a single hidden layer [66]. The number of nodes in the 
hidden layer is set to a default of 10. This number can be increased to enable a better model fit.  
 
To select an appropriate algorithm for a dataset, we divide the data into 3 groups, 70% of the data 
is used for training, while 15% of the data is used for validation and the remaining 15% is used for 
testing. The number of nodes in the hidden layer is initially set to default. Each dataset is run using 
all three algorithms (LM, SCG and BFG), and the sum of square error (SSE) and number of epoch, 
or iteration, are recorded. The algorithm that yields a low SSE with a reasonable epoch is selected 
to carry forward. 
 
Once the training algorithm is established, we adjust the number of nodes to possibly improve the 
SSE and epoch. The number of nodes that yields a low SSE with a reasonable epoch is selected.  
 
To ensure we have a good model, we evaluate the regression plots of network outputs with respect 
to target for training, validation and test sets. For a good model fit, most of the data should fall 
along a 45 degree line, where the network outputs are equal to the targets.  
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In addition, an error (errors = targets – output) histogram is plotted to obtain additional verification 
of network performance. For a good model fit, the error distribution should be roughly normal 
centers around 0.  
 
 
4.2.4 Comparison between Conventional and Neural Network Approaches 
 
To evaluate how accurately each approach characterizes the data, the following criteria are used 
[68]:  
 
(1) Observed vs Predicted: After an appropriate model is established for each approach, product 
aggregate level (𝑌𝑝𝑟𝑜𝑑) is estimated using the models and the feed aggregate (𝑌𝑓𝑒𝑒𝑑) data. The 
predicted product aggregate (?̂?𝑝𝑟𝑜𝑑) is then compared with the actual product aggregate 
(𝑌𝑝𝑟𝑜𝑑). Deviation from the diagonal and the presence of any significant trend indicate a 
potential lack of fit.  
 
(2) Residual Plot: Ordinary residuals are the difference between the observed (𝑌𝑝𝑟𝑜𝑑) and model-
predicted (?̂?𝑝𝑟𝑜𝑑) values 
 
 





where i = 1,2,3,4 … n. Positive residuals indicate that the model overpredicts the observation, 
whereas negative residuals indicate that model underpredicts the observation. The presence of 
any obvious trend indicates a potential lack of fit.  
 
(3) SSE: Another metric of goodness of fit is the square difference between observed and 
predicted values, or the sum of square error (SSE)  
 









       
where a small SSE indicates a better  model fit.  
 
 
4.2.5 Simulation to Define Acceptance Criteria  
 
During process development, it is critical to define appropriate acceptance criteria for process 
intermediate aggregate level. Based on the safety and efficacy testing, we are often given a quality 
specification for the product. Subsequently, we have to derive an appropriate specification for the 
feed, which is used to determine whether or not to proceed with the step.  
If the feed aggregate level is outside of the acceptance limit, then we might not want to proceed 
with the step, since the product is less likely to meet the pre-defined specification. Although a 
narrower in-process specification increases the probability of meeting the product specification, it 
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could potentially reject batches that would have otherwise met the final drug specification. Hence, 
it is critical to establish an accurate in-process specification. 
 
        
4.2.5.1 Conventional Approach 
 
To capture the variability of aggregate reduction(𝑌𝑟𝑒𝑑), Monte Carlo simulation is performed using 
a normal distribution, with the mean and standard deviation of the aggregate reduction from the 
original dataset.  The predicted product aggregate level is calculated by subtracting the 
simulated(𝑌𝑟𝑒𝑑) from the feed. This process is repeated 300 times, and the mean and 90% 
confidence interval are generated for each feed aggregate level. Based on the pre-specified product 




4.2.5.2 Neural Network Approach 
 
Each time a neural network is trained, it can result in slightly different solution due to different 
initial weight and bias values and different divisions of data into training, validation and test sets. 
To account for this variability, the neural model is run on each of the dataset for 300 times, and 
the mean and 90% confidence interval are computed. Based on the pre-specified product aggregate 
level, we can predict what the corresponding feed (or product from previous step) aggregate level 
is from the mean curve. 
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If we need to adopt a more conservative approach, we can use the 90% confidence interval curve, 
instead of the mean curve, to predict the feed aggregate acceptance limit. To evaluate the 
acceptance limit set by each approach, we compare the mis-specification (type I and type II error) 






In this study, we try to understand the process capability of a chromatography step, or the aggregate 
reduction across the step. Figure 4.5 shows the correlation between the chromatography feed and 
product aggregate level from monoclonal antibody purification processes of four different 
products. Figure 4.6 shows the aggregate reduction with respect to the feed aggregate level, 
respectively. The aggregate reduction increases at higher feed aggregate level, as most of the 
higher-order aggregates are cleared by the chromatography step.  
 
In process 4, there seems to be an initial decrease in aggregate level at the feed level of 1.5 – 2.5%. 
This could be attributed to the composition of the aggregate in the feedstream. For instance, there 
might be a larger percentage of dimers, which are harder to be removed, present in the feed that 
has a 2.5% total aggregate. Hence, the reduction of aggregate for this particular feedstream is 





4.3.1. Neural Network Training Algorithm and Architecture 
 
To select an appropriate training algorithm for each of the process, all datasets are run with three 
approximation algorithm (LM, SCG and BFG), with the initial number of hidden neurons set at 
default. SSE and number of epoch are used as the screening criteria.  
 
Table 4.1 shows the algorithm and number of nodes for each process. For all four processes, 
Levenberg-Marquardt (LM) is selected as the best training algorithm, which results in a low SSE 
and epoch. LM is indeed the most common algorithm for function approximation in neural network 






Fig 4.5 Chromatography feed vs. product aggregate levels in purification processes from four different products. The x-






Fig 4.6 Chromatography feed vs. product aggregate reduction levels in all four processes. The x-axis shows 
the feed aggregate level, and the y-axis shows the aggregate reduction level.  
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After we establish the training algorithm, different numbers of nodes (8, 10, 12, 14,16,18,20 and 




Process Algorithm Number of Nodes 
1 LM 10 
2 LM 14 
3 LM 12 
4 LM 22 




4.3.2 Conventional Approach Model 
 
For the conventional approach, we assume that aggregate reduction is constant, irrespective of the 
feed aggregate level. Table 4.2 shows the modeling equation for each of the process, where ?̂?𝑝𝑟𝑜𝑑,𝑖 
is the predicted product aggregate level, 𝑌𝑓𝑒𝑒𝑑,𝑖 is the feed aggregate level, and ?̅?𝑟𝑒𝑑 is the average 















Table 4.2 Conventional Model Equations 
 
4.3.3 Comparison between Conventional and Neural Network Approach 
 
To evaluate the accuracy of the model that we establish using the conventional and neural network 
approaches, we analyze the observed vs. predicted plot, residual plot and SSE. Figure 4.7 shows 
the predicted product aggregate level compared to the actual aggregate level, using either the 
conventional or neural network approach. The red line represents the 45o line, and the green line 
is the least squares regression (LSR) line. With the neural network approach, most of the data fall 
on the 45o line, and the LSR line overlaps with the 45o line, suggesting a near-perfect fit. However, 
with the conventional approach, some of the data, as well as the LSR line, deviate from the 45o 
line, suggesting a lack of fit. 
 
In addition to analyzing the obs. vs. pred plot, we evaluate the residual plot. As shown in Figure 
4.8, the conventional approach seems to underestimate the product aggregate level at low feed 
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aggregate level, and overestimate at high feed aggregate level. This is because the conventional 
approach assumes constant aggregate reduction throughout. In fact, aggregate reduction tends to 
be lower at low feed aggregate level, and higher at high feed aggregate level, as shown in Fig 4.6. 
Conversely, with the neural network approach, the residuals scatter around the zero reference line 
(red line), without any significant trend, suggesting a better fit than the conventional approach.  
 
Finally, another important metrics to evaluate model accuracy is the SSE. As seen in Table 3, in 
all four processes, the neural network model predictions result in much lower SSE compared to 
the conventional method.  
 
 
Process Conventional Neural 
Network 
1 91.00 34.37 
2 1068.48 52.22 
3 1777.49 54.56 
4 884.61 14.87 
Table 4.3 SSE of Model using Conventional and Neural Network Approaches 
 
 
As a result, prediction using the neural network approach seems to be superior to the conventional 
approach, as suggested by the observed vs. predicted plot, residual plot and SSE. Rather than 
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assuming the aggregate reduction is constant across all feed aggregate level, the neural network 
analyzes each pair of the feed and product aggregate level, and generates a model with appropriate 
weight to capture the correlation between the feed and product [60]. In addition, the neural network 








Fig 4.7 Observed vs. Model Predicted Aggregate Level calculated using Conventional and Neural Network Approaches. The x-axis shows 
the predicted product aggregate level, and the y-axis shows the actual product aggregate level. The top panel of each process shows the conventional 
approach results, whereas the bottom panel shows the neural network approach results. The red line is the 45o reference line, in which the predicted 
outputs are equal to the actual aggregate level, and the green line is the least squared regression (LSR) line based on the relationship between the 






Fig 4.8 Model Predicted Aggregate level vs. Residuals from Conventional and Neural Network Approaches. The x-axis represents the predicted 
product aggregate level, and the y-axis represents the residual level, which is the difference between the predicted and the actual product aggregate 




4.3.4 Definition of Process Acceptance Criteria 
 
Figure 4.9 shows the simulated feed and product aggregate levels. The red horizontal line indicates 
the pre-defined product specification, and the red, blue and green vertical lines represent the 
acceptance limits for the feed aggregate level, estimated by the internal mechanistic model, neural 
network and conventional approach, respectively. Compare to the conventional approach, the 
neural network approach has a lower Type I error, or is less likely to reject batches that in fact 
meet the product specification. The neural network estimates are also closer to the internal 





1 3.46 3.27 3.42 
2 6.71 6.83 6.70 
3 8.15 8.02 8.22 
4 6.19 5.01 6.27 
Table 4.4 Feed Acceptance Limit calculated using the Internal Model, Conventional and Neural 
Network Model 
 
Process Convectional Neural 
Network 
1 3.46% 5.77% 
2 10.17% 8.77% 
3 2.16% 3.69% 
4 0% 4.27% 







Figure 4.9 Feed and Product Aggregate Level, with product specification (red horizontal line), and associated feed acceptance limits derived 
from internal model (red dashed vertical line), conventional model (green dashed line) and Neural Network model (blue dashed line). 
 102 
 
Table 4.5 shows the error %, or the percentage of batches that meets the feed acceptance limit but 
fails the product specification. With the neural network approach, although we have a slightly 
higher error %, we are able to capture more batches that meet the product specification, and less 
likely to have Type I error. Since the error% with the neural network approach is less than 10%, 
which is our internal standard, we believe that the neural network is a better approach since the 
cost of falsely rejecting a manufacturing batch can be consequential.  
 
In addition, depending on what data are available for the feed and aggregate level, using the 
conventional, or simply taking the average of the aggregate reduction of the available data can 
create some type of bias. For example, if mostly high feed aggregate data are available, then the 
average reduction might be overestimated, and the product aggregate level would be 
underestimated using the conventional approach. Hence, the distribution of the available data can 
affect the error% of the conventional approach. However, neural network can learn from both high 
and low feed aggregate data, and derive the relationship between the feed and product aggregate 






Setting appropriate in-process acceptance criteria is important in ensuring success in drug 
manufacturing, and increasing the likelihood that drug substance or product will meet the final 
release specification. In order to establish accurate feed acceptance criteria, it is critical to 
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understand process capability, and accurately characterize the relationship between the feed and 
product aggregate level.  
 
In this chapter, we compare the performance of the conventional approach, which is widely 
practiced in industry, and the neural network approach. While the conventional approach is much 
simpler, it assumes that the impurity reduction is constant, and thus might not be able to provide a 
good estimate of process capability in cases where impurity reduction is feed dependent. In 
contrast, neural network model is better able to characterize the relationship between the feed and 
product aggregate level, and to estimate the feed aggregate acceptance limit based on the product 
aggregate specification.  Our study suggests that it is beneficial to consider using neural network 















5 Conclusions & Future Work 
 
Monoclonal antibody has become a major therapeutic agent for various diseases, such as oncology, 
immunology and infectious diseases. As compared to small molecules drugs, monoclonal antibody 
drugs tend to be more efficacious, with less off target effects. Hence, the demand for monoclonal 
antibody drugs have increased significantly over the last decade, with the sales of monoclonal 
antibody drugs reached $75 billion in 2013.  
 
To meet the increased demand in monoclonal antibody drugs, biopharmaceutical companies have 
developed new process technologies, such as extended cell culture, continuous chromatography, 
tangential flow filtration, to improve the productivity and output of upstream and downstream 
production. In addition, the ensure the continuously supply of drug products, as well as the quality 
of the drug products, FDA has mandated process characterization and validation as part of the drug 
approval package. The process characterization and validation activities should enable an 
identification of critical quality attributes (CQA), critical process parameters (CPP) and the 
corresponding acceptance criteria, and operating ranges, respectively.  
 
To minimize product failure, and increase competitiveness of their products, biopharmaceutical 
companies have developed significant efforts to (1) monitor and understand the trend of drug 
production performance, specifically focusing on the yield, and critical product attribute; and (2) 
develop appropriate in process specification, which also serves as forward processing criteria to 
determine whether or not the process a specific step. In addition, with the intense competition 
within the industry, it is important for biopharmaceutical companies to develop drugs that not only 
show superior efficacy and safety, but also are cost effective.  
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This chapter summarizes the efforts made in this thesis to develop decision framework and tools 
to identify development strategies for manufacturing cost reduction, leverage historical 
manufacturing batches to predict future production performance, and finally develop in process 
specification based on process capability. Furthermore, it also points out a number of future 
developments that will increase the robustness, consistency and economy of the monoclonal 
antibody production process.   
 
 
5.1. Overall Conclusions  
 
The primary aim of this thesis has been the design and development of decision – support 
framework and quantitative tools that is capable of optimizing and simulating monoclonal 
antibody manufacturing process, predicting process performance and setting in process 
specification for critical quality attributes. The resulting tool described throughout this thesis is 
capable of facilitating more informed decision making when evaluating which optimization 
strategies to adopt, if a potential process deviation will arise based on past and recent process 
performance, and whether or not to process a step forward based on the intermediate specification. 
The aim of this body of work was realized through a number of objectives that formed the basis 
of each of the preceding chapters. These chapters clearly demonstrate that the framework is 
powerful, and more reliable for process optimization, monitoring and control.  
 
Chapter 2 details the development approach to establish a decision – support framework to 
support process optimization to reduce manufacturing cost of goods. This is achieved through a 
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combination of analyses, such as risk assessment, Design of Experiment (DoE) and Principal 
Component Analysis (PCA). The risk assessment, of Failure Mode Effects Analysis (FMEA), 
enables the identification of a list of potential critical parameter that may have significant impact 
on the attribute we are evaluating, in this case cost of goods. These parameters are then carried 
onto the DoE study, through which parameters that have statistically significant impacts on the 
cost of goods are identified, and these parameters are now call critical process parameters, or CPPs. 
This is what has been done frequently in the biopharmaceutical industry.  
 
While the DoE studies enable the identification of critical process parameters, sometimes it doesn’t 
give further insights into the relative importance of each parameter. Consequently, this makes the 
process development very challenging, because there isn’t much guidance on how we should 
prioritize the process development strategies, or which parameters to optimize first given the 
limited resources available. Hence, we introduce another tool, principal component analysis, which 
can give the relative contribution of each critical parameter to the cost of goods. In our case study, 
the combination of DoE and PCA has effectively identified and prioritized parameters for further 
optimization to reduce cost of goods.  
 
Monoclonal antibody production process is inherently more variable than small molecule drug 
production process, mostly due to the large variability in the cell culture process. Hence, when we 
are analyzing the monoclonal antibody process, it is important to capture this variability, 
specifically variability in titer, and in chromatography and filtration yields. Rather than using a 
deterministic approach, we have shown that using a stochastic approach, or Monte Carlo 
simulation, is more effective in understanding the impact on cost of goods when a specific process 
 107 
 
parameter is optimized. The framework illustrated in chapter 2 not only enables us to identify a 
list of critical process parameters, but also enables us to understand what the impact is when some 
of these parameters are optimized.  
 
In addition to control the cost of monoclonal antibody manufacturing, biopharmaceutical 
companies closely monitor and understand the trend of their manufacturing batches, to minimize 
potential batch failures. Chapter 3 illustrates the use of Bayesian approach, and also historical 
manufacturing data to predict the future trend of batch performance, such as process yield, and 
critical quality attributes.  
 
The conventional method, or the method that’s typically practiced in the industry, is to take the 
average of the historical batches and assume the future batches have the same average 
performance. However, as shown in our case study, while the conventional method is simpler or 
more straightforward, in cases where there is inconsistency between the historical batches and the 
recent batches, the conventional approach might not be able to reflect the changes in the recent 
batches, especially when the size of the historical dataset is much larger.  
 
To address this gap, we have introduced the Bayesian approach. In contrast to the conventional 
approach, the Bayesian approach calculates the posterior mean, or the average performance for the 
future batches, by using the historical batches to form a prior belief or trend, and updating it with 




In our case study, when there is inconsistency between the historical and recent batches, the 
Bayesian method is better at predicting the mean of future batches compared to the conventional 
approaches. Conversely, when the manufacturing batches perform consistently, both approaches 
yield similar estimates, simply because there is no new information from the recent batches to 
update the historical trend.  
 
Hence, to determine which approach we should use to estimate the mean of the future batch 
performance, we need to calculate the ratio of the means between the historical and recent batches. 
As the ratio deviates from unity, it suggests there is inconsistency between the batches, and in this 
case, Bayesian approach might be able to give a more accurate estimate.  
 
Finally, in order to successfully release a manufacturing batch, the drug substance and drug 
product must pass the acceptance criteria for all critical quality attributes, to ensure safety and 
efficacy of the drug. Thus, it is important to set process intermediate specification, to ensure every 
step in the monoclonal antibody manufacturing process meet the specification, and ultimately 
increase the probability of the final drug substance and drug product meet the acceptance criteria.  
 
To accurately set the in process specification, we first understand the capability of each step to 
remove impurities, such as aggregates, HCP, DNA and leached Protein A. Subsequently, process 
intermediate specification, or acceptance criteria, can then be set based on the process capability 
and the final drug substance specification. One of the most challenging parts is to have an accurate 
understanding of the process capability, and Chapter 4 illustrates the use of neural network to 




Based on the literature survey and conversations with industry experts, there are multiple 
approaches to estimate process capability. While some approaches are more complicated, such as 
conducting a series of experimentation to challenge the chromatography resin to understand the 
maximum impurity clearance capability, the most typical approach, or the conventional approach, 
used to find the average impurity reduction is by calculating the difference between the average 
feed and product impurity level. This approach assumes that impurity removal is constant at all 
time.  
 
However, as shown in our analyses, impurity clearance sometimes depends on the feed impurity 
level. Especially in the case of aggregates, the aggregate removal is much higher when the feed 
aggregate level is higher, because the feedstream has mostly higher order aggregates and they are 
much easier to be removed. Using the conventional approach in this case would not be able to 
accurately estimate the impurity clearance level of a particular step.  
 
Hence, we propose to use neural network to estimate process capability. Unlike the conventional 
approach, the neural network approach does not assume a constant impurity removal across all 
feed impurity level. Rather, it can identify and learn correlative patterns between feed and product 
data pairs. Once trained, it may be used to predict the product impurity level based on the feed 
impurity level, or vice versa. One of the most useful properties of neural networks is its ability to 
generalize. In our study, the neural network approach has been shown to be better at estimating 




5.2 Future Work 
 
The objective of this body of work has been the design and development of a systematic framework 
to optimize and control monoclonal antibody manufacturing process. The preceding chapters have 
demonstrated how the framework has successfully fulfilled this objective. The framework is 
clearly a powerful tool for evaluating process optimization strategies, predicting the trend of 
monoclonal antibody manufacturing performance and setting in process acceptance criteria, and 
can therefore act as a strong foundation from which future work can build; several examples are 
highlighted and discussed below.  
 
In addition to evaluating the different parameters for further optimization in a mAb manufacturing 
process, the DoE-PCA and Monte Carlo simulation framework can be used to evaluate the 
different modes of chromatography, cell culture and filtration technologies in the production 
process. For example, during process development, there are multiple instances that we have to 
decide what modes of chromatography, such as mixed mode, cation exchange, hydrophobic 
interaction chromatography, to use in a process. In addition to consider process fit and flexibility, 
we need to evaluate how each mode impact the different attributes, such as overall throughput, 
product quality and cost. The DoE- PCA and Monte Carlo simulation framework can easily enable 
us to visualize the impact.  
Furthermore, many biopharmaceutical companies have started to adopt new technologies, such as 
continuous cell-culture techniques [69, 70], single pass tangential flow filtration (SPTFF) [71], 
and continuous precipitation [72]. Again, the DoE-PCA and Monte Carlo simulation can be used 
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here to evaluate each of these technologies, compare it with the traditional manufacturing platform 
and facilitate decision making on whether or not to invest in a new technology.  
 
In our analyses, we have illustrated how neural network was used to understand impurity clearance 
capability of each step, and therefore using such information to help setting process intermediate 
specification. In addition to the application in setting specification, the neural network approach 
can be used to evaluate the different emerging technologies mentioned above. Impurity clearance 
capability is often one of the important criteria during technology evaluation.  
 
Finally, in our case study, we have used Bayesian approach to predict future manufacturing batch 
performance. The same approach can also be used to forecast the demand for a particular drug, as 
well as the supply, or the annual throughput. This information will be critical in accurate supply 
chain planning, and avoid disruption or shortage in drug supply.  
 
In conclusion, the future work that has been outlined looks to increase the scope and application 
of the systematic framework not only in monoclonal antibody manufacturing, but also in 
technology evaluation and supply chain planning. Over the next decade, more and more new 
technologies will be developed to facilitate drug manufacturing, for better process fit, productivity, 
flexibility and improved process economics. Before making significant investments in these new 
technologies, it is very important for biopharmaceutical companies to conduct an in-depth risk and 
benefit analysis, compare the existing with the emerging technologies, and leverage appropriate 
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7.  Appendix  
7.1 Chapter 2 Appendix 
7.1.1 Tables 
Table A7.1.1.1 Typical Parameters and Setpoints in Upstream Steps 
Parameter Unit Setpoint 
Cell Culture (Upstream) 
N-2 Bioreactor 
Volume L 200 
Medium Fill Volume L 175 
Medium Transfer in Rate L/h 117 
Temp oC 37 
N-1 Bioreactor 
Volume L 1300 
Medium Transfer in Rate L/h 708 
Temp oC 37 
Production Bioreactor 
Volume L 20000 
Feed Amount L 1200 
Feed Flow Rate L/h 3.6 
Temp oC 37 
Reaction Time day 14 
Target Concentration g/L depends on experimental condition 
Monoclonal Antibody Cost $/mg 3 
Primary Recovery (Upstream) 
Centrifugation   
Biomass Removal % 98 
Sedimentation Efficiency % 30 
Volumetric Throughput per Unit L/h 1800 
Number of Cycle per Batch  1 
Depth Filtration 
Flux L/m2·min 4.2 
Biomass Removal % 100 
Filter Pore Size μm 0.2 
Filter Area m2 10 
Unit Cost $ 1000 




Table A7.1.1.2 Typical Parameters and Setpoints in Downstream Steps 
Parameter Unit Setpoint 
Purification (Downstream) 
Protein A 
Column Volume L 143 
Resin Cost $/L 14000 
Resin Replacement Frequency Cycles 65 
Resin Binding Capacity g/L 28.6 
Eluant Volume in Product Stream 
Bed 
Volume 2 
Elution Linear Velocity cm/min 5 
Number of Cycles per Batch  6 
Virus Inactivation 
Low pH Hold Time min 60 
Filter Flux L/m2·min 6.8 
Filter Area m2 10 
IEX I 
Column Volume L 76 
Resin Binding Capacity g/L 199 
Resin Cost $/L 2445 
Replacement Frequency Cycles 40 
Number of Cycles per Batch  1 
IEX II 
Column Volume L 105 
Resin Binding Capacity g/L 31.7 
Eluant Volume in Product Stream 
Bed 
Volume 5 
Resin Cost $/L 2290 
Replacement Frequency Cycles 40 
Number of Cycles per Batch  4 
Viral Filtration 
Filter Cost Per Unit $ 1000 
Filter Flux L/m2·min 0.7 
Filter Area m2 10 
UFDF 
Membrane area m2 2.95 
Replacement Frequency Cycles 30 
Number of Diavolume Diavolume 6 
Concentration Factor  5 
Filtrate Flux L/m2·h 35 
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1 34.37 8103.14 
2 52.22 53.5 
3 54.56 66.67 












































































































7.2 Chapter 3 Appendix 
7.2.1 Tables 
Table 7.2.1.1 Host Cell Protein (HCP) level at Different Manufacturing Batches 
  ID 
HCP Level 
(ppm) 
Batch 1 1 48.015 
  2 44.352 
  3 50.589 
  4 54.054 
  5 55.341 
  6 60.984 
Batch 2 7 174.24 
  8 189.09 
  9 205.92 
  10 168.3 
  11 174.24 
  12 172.26 
Batch 3 13 51.48 
  14 45.045 
  15 54.945 
  16 56.925 
  17 62.469 
  18 65.34 
Batch 4 19 38.61 
  20 46.827 
  21 63.954 
  22 72.567 
  23 53.658 
  24 39.105 
Batch 5 25 118.8 
  26 116.82 
  27 114.84 
  28 146.52 
  29 145.53 
  30 133.65 
Batch 6 31 102.96 
  32 94.446 
  33 109.89 
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  34 124.74 
  35 124.74 
  36 138.6 
Batch 7 37 104.94 
  38 90.882 
  39 97.218 
  40 100.98 
  41 93.852 
  42 106.92 




















Table 7.2.1.2 Summary of Host Cell Protein (HCP) level at Different Manufacturing Batches 
Batch #  mean std std of mean # runs 
Batch 1 52.2225 5.86787 2.395547714 6 
Batch 2 180.675 14.24706 5.816337765 6 
Batch 3 56.034 7.368686 3.008253646 6 
Batch 4 52.4535 13.70947 5.596867128 6 
Batch 5 129.36 14.5185 5.927152773 6 
Batch 6 115.896 16.3427 6.671878596 6 





















Table 7.2.1.3 Protein A Yield level at Different Manufacturing Batches 
  ID 
Protein A Yield 
(%) 
Batch 1 1 80.75 
  2 83.6 
  3 84.55 
  4 97.85 
Batch 2 5 78.85 
  6 82.65 
  7 92.15 
  8 85.5 
  9 82.65 
  10 87.4 
Batch 3 11 86.45 
  12 95.95 
  13 95 
  14 91.2 
  15 92.15 
  16 93.1 
Batch 4 17 81.7 
  18 87.4 
  19 69.35 
  20 82.65 
  21 82.65 
  22 86.45 
Batch 5 23 78.85 
  24 102.6 
  25 80.75 
  26 84.55 
  27 85.5 
  28 84.55 
Batch 6 29 83.6 
  30 83.6 
  31 84.55 
  32 83.6 
  33 85.5 
  34 90.25 
Batch 7 35 66.5 
  36 69.35 
  37 69.35 
  38 66.5 
 129 
 
  39 73.15 
  40 71.25 
Batch 8 41 73.15 
  42 75.05 
  43 74.1 
  44 78.85 
  45 78.85 
  46 83.6 
Batch 9 47 74.1 
  48 79.8 
  49 79.8 
  50 78.85 
  51 78.85 
  52 88.35 


















Table 7.2.1.4 Summary of Protein A level at Different Manufacturing Batches 
Batch # mean std std of mean # runs 
Batch 1 86.6875 7.614829 3.807414641 4 
Batch 2 84.86667 4.602029 1.878770283 6 
Batch 3 92.30833 3.367702 1.374858579 6 
Batch 4 81.7 6.471167 2.641842791 6 
Batch 5 86.13333 8.468687 3.457327163 6 
Batch 6 85.18333 2.595894 1.059769367 6 
Batch 7 69.35 2.618969 1.069189724 6 
Batch 8 77.26667 3.924623 1.602220681 6 
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7.3.1 Figures 
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